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Introduction {#embj201798250-sec-0001}
============

Transcription factor EB (TFEB) belongs to the microphthalmia family of bHLH‐leucine zipper molecules. It is involved in the biogenesis and function of the endo‐lysosomal compartment, including membrane trafficking and autophagy (Sardiello *et al*, [2009](#embj201798250-bib-0054){ref-type="ref"}; Settembre *et al*, [2011](#embj201798250-bib-0058){ref-type="ref"}, [2013b](#embj201798250-bib-0061){ref-type="ref"}; Napolitano & Ballabio, [2016](#embj201798250-bib-0043){ref-type="ref"}; Raben & Puertollano, [2016](#embj201798250-bib-0050){ref-type="ref"}). Furthermore, TFEB mutation characterizes a subset of renal cell carcinoma carrying the t(6;11)(p21:q13) translocation, which leads to a *TFEB* promoter substitution with the 5′ upstream regulatory sequence of the *alpha* intronless gene (Calcagnì *et al*, [2016](#embj201798250-bib-0005){ref-type="ref"}).

TFEB recognizes E‐box‐type DNA sequences (Palmieri *et al*, [2011](#embj201798250-bib-0044){ref-type="ref"}) and resides in the cytosol, moving to the nucleus when lysosomes and autophagy are required for cell activities (Martina *et al*, [2012](#embj201798250-bib-0039){ref-type="ref"}; Settembre *et al*, [2012](#embj201798250-bib-0059){ref-type="ref"}). The functions of TFEB are mainly regulated by mTOR complex 1 (mTORc1), which integrates energy availability with cellular demand. In the presence of nutrients, mTORc1 phosphorylates TFEB and inhibits its transport into the nucleus. Conversely, under starvation conditions, when mTORc1 is inactive, unphosphorylated TFEB rapidly accumulates in the nucleus. In general terms, TFEB is involved in the pathogenesis of lysosomal storage diseases (Xu & Ren, [2015](#embj201798250-bib-0071){ref-type="ref"}) and, through its connection with mTOR pathway, in the control of energy expenditure both in physiology (Mansueto *et al*, [2017](#embj201798250-bib-0038){ref-type="ref"}) and in pathology (Perera *et al*, [2015](#embj201798250-bib-0047){ref-type="ref"}; Di Malta *et al*, [2017](#embj201798250-bib-0013){ref-type="ref"}).

An increasing number of observations suggest a pivotal role of TFEB in vascular biology. Targeted inactivation of TFEB in mice results in impaired placental vascularization and inhibits the expression of VEGF‐A in labyrinthine cells (Steingrímsson *et al*, [1998](#embj201798250-bib-0065){ref-type="ref"}). The embryonic vasculature is unable to invade the placenta, halting the exchange of nutrients and causing lethal hypoxia and embryonic lethality. During atherogenesis, the lysosomal stress induced by the accumulation cholesterol activates a TFEB response, which triggers an anti‐inflammatory (Lu *et al*, [2017](#embj201798250-bib-0036){ref-type="ref"}) and anti‐atherogenic response (Emanuel *et al*, [2014](#embj201798250-bib-0014){ref-type="ref"}). Finally, the overexpression of Tfeb in endothelial cells (ECs) promotes post‐ischemic angiogenesis through the activation of autophagic flux (Fan *et al*, [2018](#embj201798250-bib-0018){ref-type="ref"}).

Using EC‐specific loss‐of‐function mouse mutants (*Tfeb* ^EC−/−^) and cellular models, we investigated the effect of *Tfeb* deletion on the vasculature in the embryo and in newborn mice. We found that TFEB positively controls the expression of cyclin‐dependent kinase 4 (CDK4) and its deletion results in the block of cell growth and in a futile attempt to recover this process by targeting vascular endothelial growth factor (VEGF) receptor (R)‐2.

Results {#embj201798250-sec-0002}
=======

Tfeb is expressed in embryonic and post‐natal vessels {#embj201798250-sec-0003}
-----------------------------------------------------

To analyze *Tfeb* expression in the vasculature, we used constitutive knock‐in *Tfeb‐EGFP* mice. Tfeb was expressed very early in developing vessels and persisted in newborn pups. The vascular expression was heterogeneous and not generalized to all ECs (Figs [1](#embj201798250-fig-0001){ref-type="fig"}A and B, and [EV1](#embj201798250-fig-0001ev){ref-type="fig"}A), suggesting a dynamic role in the vasculature. At E9.5, Tfeb‐EGFP co‐localized with endothelial endomucin in head and in the intersomitic vessels as well as yolk sac capillaries (Fig [EV1](#embj201798250-fig-0001ev){ref-type="fig"}A). We then examined the expression of Tfeb in retina and kidney, whose vascular beds undergo post‐natal development (Gariano & Gardner, [2005](#embj201798250-bib-0020){ref-type="ref"}; Little & McMahon, [2012](#embj201798250-bib-0034){ref-type="ref"}). At p5, Tfeb‐EGFP was present in both large and small retinal vessels at the vascular front and vascular plexus (Fig [1](#embj201798250-fig-0001){ref-type="fig"}A). The analysis of renal vessels at p17 showed that Tfeb was present in glomerulus, capillaries and some small arteries (Fig [1](#embj201798250-fig-0001){ref-type="fig"}B). As reported by the whole mRNA expression analysis (Steingrímsson *et al*, [1998](#embj201798250-bib-0065){ref-type="ref"}), Tfeb‐EGFP was present in alpha‐smooth muscle actin (SMA)‐positive cells and pericytes of embryo tissues (E9.5; Fig [EV1](#embj201798250-fig-0001ev){ref-type="fig"}B and C) and retina (p5; Fig [EV1](#embj201798250-fig-0001ev){ref-type="fig"}D) as well as in renal podocytes (p17; Fig [EV1](#embj201798250-fig-0001ev){ref-type="fig"}E), as inferred by the use of specific antibodies anti‐SMA, neural/glial antigen‐2 (NG2), and podocin.

![Mouse genetic ablation of endothelial *Tfeb* leads to vascular defects\
A, B*Tfeb* expression in the vasculature (mice *n* = 10). (A) Representative images of retinal vessels (p5) (A) (scale bar: 50 μm) and (B) glomerular, arterial (scale bars: 10 μm) and interstitial vessels (scale bar: 50 μm) of kidney (p17) of *Tfeb‐EGFP* mice stained with anti‐iB4 (A), anti‐CD31 (B) and anti‐GFP (A,B).CAlterations in the embryonic vasculature in *Tfeb* ^EC−/−^ mice at E10.5 (mice *n* = 25). Representative images of whole‐mount embryos and yolk sacs (i, ii) (scale bars: 0.5 mm). Vessels of the head (iii), ocular (iv), and intrasomitic regions (v) were stained with anti‐endomucin Ab (scale bars: 100 μm).DAlteration of retinal vascular maturation in *Tfeb* ^iEC−/−^ at p5. Representative images of whole mounts of retina and immunostaining of vascular front and vascular plexus with an anti‐iB4 Ab (scale bars: 50 μm). Bar graphs indicate the percent of vascular area versus total area of the retina, the percent of vascular density, the number of branches per field, vessel diameter, the number of filopodia per field, and the length of filopodia (mice *n* = 10, mean ± SEM; \*\*\**P* \< 0.0001 versus control mice by Student\'s *t‐*test).EAlteration of the glomerular ultrastructure in *Tfeb* ^iEC−/−^ mice at p17 (mice *n* = 5). Representative transmission electron micrographs of renal tissue. Magnification: (i) ×6,000, (ii) ×20,000), (iii--iv) ×10,000, (v--vi) ×25,000; scale bars: 1 μm). Asterisks indicate the accumulation of extracellular matrix in mesangium; white and black triangles indicate the fusion of podocyte foot processes and the lack of endothelial fenestrae, respectively.](EMBJ-38-e98250-g002){#embj201798250-fig-0001}

![Different cells types express Tfeb in embryos, yolk sac, retina, and kidney\
A*Tfeb* expression in embryos at E9.5 (embryos *n* = 6). Representative images of head (details a, b, c), intrasomitic region (details a, b, c), and yolk sac of *Tfeb‐EGFP* embryos stained with anti‐GFP and anti‐endomucin Abs (scale bars: 100 μm).B--ETfeb expression in ECs and smooth muscle cells in embryos, retina, and kidney. Representative images of *Tfeb‐EGFP* embryos (E9.5) (B), yolk sac (E9.5) (C), retina (p5) (D), and renal glomerulus (E) (embryos and mice *n* = 6) stained with anti‐CD31, anti‐alpha SMA, anti‐NG2, anti‐podocin, and anti‐GFP Abs (scale bars: 100 μm).](EMBJ-38-e98250-g003){#embj201798250-fig-0001ev}

Tfeb expression in ECs is essential for vascular development {#embj201798250-sec-0004}
------------------------------------------------------------

To investigate the role of Tfeb in embryonic vessel development, we interbred *Tfeb* ^floxed^ mice (Settembre *et al*, [2013a](#embj201798250-bib-0060){ref-type="ref"}) with *Tie2‐Cre* mice, which allows EC‐specific gene targeting from E8.5 (Kisanuki *et al*, [2001](#embj201798250-bib-0030){ref-type="ref"}). *Tie2‐Cre* ^*ˉ*^ */Tfeb* ^floxed^ (control) and *Tie2‐Cre* ^*+*^ */Tfeb* ^−/+^ (*Tfeb* ^EC−/+^) embryos survived, while *Tie2‐Cre* ^*+*^ */Tfeb* ^−/−^ (*Tfeb* ^EC−/−^) mice were absent among the different progenies (*n* = 8), indicating embryonic lethality.

At E9.5, analysis of control, *Tfeb* ^EC−/+^, and *Tfeb* ^EC−/−^ embryos showed indistinguishable phenotypes from normal vasculature (Fig [EV2](#embj201798250-fig-0002ev){ref-type="fig"}A). At E10.5, *Tfeb* ^EC−/+^ mice were similar to control, while *Tfeb* ^EC−/−^ presented an altered vascular phenotype (Fig [1](#embj201798250-fig-0001){ref-type="fig"}C). Indeed, embryos and yolk sacs from *Tfeb* ^EC−/−^ mice were smaller and paler than controls (Fig [1](#embj201798250-fig-0001){ref-type="fig"}C), with evident hypoxic areas (Fig [EV2](#embj201798250-fig-0002ev){ref-type="fig"}B). Whole‐mount (i, ii) and endomucin staining of the head (iii), ocular (iv), and intersomitic regions (v) displayed vascular defects characterized by excessive fusion into irregular dilated vessels, reduced branching, and failure to follow the normal anatomical patterns seen in control mice. Furthermore, the intersomitic region was characterized by reduced vascular invasion into somitic tissues and the presence of avascularized zones (Fig [1](#embj201798250-fig-0001){ref-type="fig"}C). The percentage of point prevalence of vascular defects in *Tfeb* ^EC−/−^ (*n* = 12) and control embryos (*n* = 13) at E10.5 was respectively 83 and 16%.

![*Tfeb* deletion in embryos and pups\
EC *Tfeb* deletion does not induce alterations in the embryonic vasculature at E9.5 (embryos *n* = 6). Representative images of whole‐mount embryos (i) (scale bars: 0.5 mm). Vessels of the head (ii), ocular (iii), and intrasomitic regions (iv) were stained with anti‐endomucin Ab (scale bars: 100 μm).EC *Tfeb* deletion induces embryonic hypoxia at E10.5 (embryos *n* = 6). Representative images of vessels and tissues of the head (i) and intrasomitic region (ii) of control and *Tfeb* ^EC−/−^ embryos stained with anti‐endomucin (red) and the hypoxic marker pimonidazole (green; scale bars: 100 μm).Expression of Tie2 and markers of the endothelial and hematopoietic lineages in Tfeb^EC−/−^ yolk sacs at E9.5. Bar graphs indicate the percentage of yolk sac Tie2^+^ cells or Flk^+^ or CD31^+^ or CD117^+^/CD41^+^ and CD117^+^/CD71^+^ within the Tie2^+^ population (*n* = 3, mean ± SEM; \**P* \< 0.01 versus control mice by Student\'s *t‐*test).Genotype of *Tfeb* ^iEC^ mice. Schematic representation of murine *Tfeb,* the targeted allele and the knockout allele (delta allele), and qPCR analysis of mRNA encoded by *Tfeb* exon 5--6 in lung ECs and epithelial cells isolated from control, *Tfeb* ^iEC−/+^, and *Tfeb* ^iEC−/−^ mice. Data are expressed as relative fold‐change compared with the expression in control mice after normalization to the housekeeping gene TBP (mice *n* = 3, mean ± SEM; \**P* \< 0.01 and \*\**P* \< 0.001 versus control mice by Student\'s *t‐*test).Tfeb expression in renal tissue of control and *Tfeb* ^iEC−/−^ mice (p17). Representative images of renal glomerulus, artery, interstitial vessels, and the surrounding tissue of control and *Tfeb* ^iEC−/−^ mice (mice *n* = 6). Tissues were stained with anti‐CD31 and anti‐GFP Abs (scale bars: 100 μm).](EMBJ-38-e98250-g005){#embj201798250-fig-0002ev}

Since Tie2 is also expressed by hematopoietic precursors at E8.5 (Takakura *et al*, [1998](#embj201798250-bib-0067){ref-type="ref"}), we evaluated the effects of *Tfeb* deletion on the maturation of this system. The expression of markers characterizing the hematopoietic and endothelial lineages, together with Tie2, was analyzed in yolk sacs at E9.5. The percentage of Tie2^+^ cells in the control was similar to that of *Tfeb* ^EC−/−^ yolk sacs as well as the abundance of early endothelial precursors identified as Tie2^+^/Flk^+^ and Tie2^+^/Flk^+^/CD31^+^. Interestingly, we observed a slight reduction in the Tie2^+^/CD117^+^/CD41^+^ cells and Tie2^+^/CD117^+^/CD71^+^ cells that represent early erythroid precursors (Fig [EV2](#embj201798250-fig-0002ev){ref-type="fig"}C).

These data support the concept that TFEB acts in a later phase of vascular development, mostly characterized by the remodeling of the primitive vascular plexus.

Tfeb is involved in retinal and renal vascular maturation after birth {#embj201798250-sec-0005}
---------------------------------------------------------------------

To overcome early embryonic lethality, we generated inducible EC‐specific mutants by crossing *Tfeb* ^floxed^ mice with *Cdh5‐CreERT2* mice (Wang *et al*, [2010](#embj201798250-bib-0070){ref-type="ref"}), thus allowing generating *Cdh5‐CreERT2* ^*+*^ */Tfeb* ^−/+^ (*Tfeb* ^iEC−/+^) and *Cdh5‐CreERT2* ^*+*^ */Tfeb* ^−/−^ (*Tfeb* ^iEC−/−^) and *Cdh5‐CreERT2* ^*ˉ*^/*Tfeb* ^floxed^ (control) mice.

The successful deletion of *Tfeb* after *in vivo* Cre induction by tamoxifen was established by detecting the Tfeb delta allele in genomic DNA after lox site recombination. In *Tfeb* ^iEC−/+^ and *Tfeb* ^iEC−/−^ mice, *Tfeb* deletion specifically occurred in endothelium as evidenced by the decrease in the exons 5 and 6 transcript only in ECs but not in epithelial cells isolated from the lungs (Fig [EV2](#embj201798250-fig-0002ev){ref-type="fig"}D). The recombination efficiency and specificity were further demonstrated by the marked Tfeb reduction in the renal vasculature of *Tfeb* ^iEC−/−^ mice (p17) but not in surrounding tissues (Fig [EV2](#embj201798250-fig-0002ev){ref-type="fig"}E).

According to the post‐natal maturation of retinal and renal vasculature, we examined the consequences of *Tfeb* deletion in the ECs of these organs. At p5, retinas from *Tfeb* ^iEC−/−^ mice showed impaired outgrowth of the superficial capillary network (Fig [1](#embj201798250-fig-0001){ref-type="fig"}D). The retinal vascular mesh was wider with a reduction of the vascular area, vascular density, branching points, and vessel size (Fig [1](#embj201798250-fig-0001){ref-type="fig"}D). The vascular front did not show any differences in the number and length of filopodia (Fig [1](#embj201798250-fig-0001){ref-type="fig"}D). The detrimental effect of *Tfeb* deletion persisted up to p15, when vascular retinal net reaches the maturity. At p10, the net features were similar to those reported at p5. From p10 to p15, the vascular area reached the size observed in control mice but the alterations in vascular density, vessel diameters, and branching points were still present (Fig [EV3](#embj201798250-fig-0003ev){ref-type="fig"}A).

![Post‐natal maturation of retinal and renal vasculature after endothelium *Tfeb* silencing\
AEC *Tfeb* deletion compromises retinal vascular maturation at p10 and p15. Representative images of immunostaining of vascular front and vascular plexus of retina of control and *Tfeb* ^iEC−/−^ mice (p10, p15) with an anti‐iB4 Ab (scale bars: 50 μm).B--DEC *Tfeb* deletion compromises glomerular development and renal vascularization at p17. (B) Representative images of renal trichrome staining of control and *Tfeb* ^iEC−/−^ mice at p17 (original magnification x10, scale bars: 25 μm). (C) Bar graph indicates the CD31^+^ vascular area in control and *Tfeb* ^iEC−/−^ mice (p17; mice *n* = 5, mean ± SEM; \*\**P* \< 0.001 versus control mice by Student\'s *t‐*test). (D) EC *Tfeb* deletion compromises renal vascularization at p27. Bar graph indicates the CD31^+^ vascular area in control and *Tfeb* ^iEC−/−^ mice (p27; mice *n* = 5, mean ± SEM; \*\**P* \< 0.001 versus control mice by Student\'s *t‐*test).EEC *Tfeb* deletion correlates with collagen deposition in kidney at p27. Representative images of immunostaining of kidney of control and *Tfeb* ^iEC−/−^ mice (p27) with anti‐collagen I, anti‐collagen V, and anti‐collagen IV antibodies (scale bars: 50 μm). Quantification area per field (mean ± SEM): collagen I: 26,107.2 ± 3,200.82 μm^2^ in control mice versus 43,069 ± 9,754.7 μm^2^ in *Tfeb* ^iEC−/−^ mice, mice *n* = 4, *P* = 0.02 versus control mice by Student\'s *t‐*test; collagen V: 33,500.4 ± 4,201 μm^2^ in control mice versus 47,007.9 ± 6,287.7 μm^2^ in *Tfeb* ^iEC−/−^ mice, mice *n* = 4, *P* = 0.04 versus control mice by Student\'s *t‐*test; collagen IV: 10,972.12 ± 1,856.8 μm^2^ in control mice versus 17,525.07 ± 2,106.58 μm^2^ in *Tfeb* ^iEC−/−^ mice, mice *n* = 4, *P* = 0.03 versus control mice by Student\'s *t‐*test)](EMBJ-38-e98250-g007){#embj201798250-fig-0003ev}

Correct assembly of the glomerular vasculature is required for filtration barrier function (Bartlett *et al*, [2016](#embj201798250-bib-0003){ref-type="ref"}). At p17, *Tfeb* ^iEC−/−^ kidneys were smaller (% area of *Tfeb* ^iEC−/−^ mice versus control 72.6 ± 7.9%; mice *n* = 3, *P* \< 0.01), characterized by poorly developed glomeruli (Fig [EV3](#embj201798250-fig-0003ev){ref-type="fig"}B) and reduced volumes (20.53 ± 2.50 × 10^4^ μm^3^ for control mice and 14.43 ± 3.27 × 10^4^ μm^3^ for *Tfeb* ^iEC−/−^; mice *n* = 3, *P* \< 0.002). The altered glomerular development paralleled the reduced CD31^+^ endothelial area in *Tfeb* ^iEC−/−^ kidneys (p17; Fig [EV3](#embj201798250-fig-0003ev){ref-type="fig"}C), which persisted up to p27 (Fig [EV3](#embj201798250-fig-0003ev){ref-type="fig"}D). Transmission electron microscopy showed deep alterations in glomerular structure, with expansion of the mesangium by deposition of extracellular matrix, focal loss of podocyte foot processes, and endothelial fenestration (Fig [1](#embj201798250-fig-0001){ref-type="fig"}E). According to the increased deposition of extracellular matrix in *Tfeb* ^iEC−/−^ (Fig [1](#embj201798250-fig-0001){ref-type="fig"}E), we observed a significant accumulation of collagen IV along capillaries, and collagen I in the interstitium, while collagen V was only moderately increased (Fig [EV3](#embj201798250-fig-0003ev){ref-type="fig"}E), supporting the hypothesis that *Tfeb* deletion could be instrumental in renal fibrosis.

In *Tfeb* ^iEC−/−^ mice, we did not observe any alterations of the ratio between vascular muscle cells and ECs both in retina (ratio NG2 area/IB4^+^ vascular area 1.2 ± 0.1 in control mice and 1.2 ± 0.3 in *Tfeb* ^iEC−/−^; mice *n* = 4, *P* = ns) and in renal glomeruli (ratio podocytes/CD31^+^ vascular area 1 ± 0.1 in control mice and 0.9 ± 0.1 in *Tfeb* ^iEC−/−^; mice *n* = 4, *P* = ns). These data support the role of the endothelial dysfunction in the histological alterations of the retina and kidney observed after *Tfeb* deletion.

Tfeb deletion reduces the proliferation of ECs {#embj201798250-sec-0006}
----------------------------------------------

The main processes characterizing vascular development are the proliferation and the migration of ECs and their relationships with extracellular matrix (Carmeliet & Jain, [2011](#embj201798250-bib-0006){ref-type="ref"}). Therefore, to understand the vascular defects observed *in vivo*, we studied ECs lacking TFEB by analyzing their growth, motility, and morphogenetic capability when layered on extracellular matrix.

The *in vivo* analysis of Ki‐67^+^ EC nuclei at p5 and p17 indicated a marked reduction in proliferating ECs in both the retina (37% in vascular front and 50% in vascular plexus) and kidney vessels (30%) of *Tfeb* ^iEC−/−^ mice (Fig [2](#embj201798250-fig-0002){ref-type="fig"}A and B). Of note, in kidney the total number of Ki‐67^+^ cells per field was not modified in *Tfeb* ^iEC−/−^ mice compared to control (Fig [2](#embj201798250-fig-0002){ref-type="fig"}B), indicating that the proliferation rate of other cell types was not modified and suggesting that the impaired EC growth is instrumental in the alteration of renal maturation.

![*Tfeb* deletion reduces EC proliferation in vivo\
A, BReduced EC proliferation in the retina (p5) and kidney (p17) of in *Tfeb* ^iEC−/−^ mice. (A) Representative images of vessels of the vascular front and vascular plexus in the retina of control and *Tfeb* ^iEC−/−^ mice stained with anti‐iB4 and Ki‐67 antibodies (scale bars: 50 μm). Bar graph indicates the percentage of EC Ki‐67^+^ nuclei versus total nuclei co‐localized with iB4^+^ vessels (mice *n* = 6, mean ± SEM; \*\**P* \< 0.001 and \**P* \< 0.01 versus control mice by Student\'s *t‐*test). (B) Representative images of vessels of the kidney in control and *Tfeb* ^iEC−/−^ mice stained with anti‐CD31 and Ki‐67 antibodies (scale bars: 50 μm). Bar graph indicates the percent of EC Ki‐67^+^ nuclei versus total nuclei co‐localized with CD31^+^ vessels (mice *n* = 6, mean ± SEM; \*\**P* \< 0.001 versus control mice by Student\'s *t‐*test). Podocin staining is shown to glomerular localization.C, D*TFEB* silencing reduced EC proliferation. Representative graph of scr‐shRNA and sh‐TFEB ECs treated for 24 h with FCS (20%) or VEGF‐A (30 ng/ml). (C) DNA incorporation of EdU was detected by flow cytometry. The percentage of proliferating cells is indicated (*n* = 4, mean ± SEM; \*\*\**P* \< 0.0001 versus scr‐shRNA ECs by Student\'s *t‐*test). (D) DNA content was determined by propidium iodide staining and assessed by fluorescence‐activated cell sorter analysis (representative experiment out of 4 with similar results).E*TFEB* silencing reduced human EC morphogenesis. Representative images of tube‐like structure of scr‐shRNA and sh‐TFEB human ECs stained with phalloidin‐555. Bar graph indicates the percentage of phalloidin^+^ area in sh‐TFEB and scr‐shRNA ECs (scale bars: 0.25 mm; *n* = 6, mean ± SEM; \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).](EMBJ-38-e98250-g004){#embj201798250-fig-0002}

Before evaluating the effect of TFEB deletion *in vitro*, we experimentally verified whether TFEB mechanism of action in ECs was similar to that described in other cell types. In EC standard culture conditions, we showed a cytosolic and nuclear endogenous expression of TFEB (Fig [EV4](#embj201798250-fig-0004ev){ref-type="fig"}A). Furthermore, when ECs were treated with Torin, an mTOR inhibitor that mimics starvation conditions and activates TFEB (Settembre *et al*, [2012](#embj201798250-bib-0059){ref-type="ref"}), we observed an increase in its nuclear translocation (Fig [EV4](#embj201798250-fig-0004ev){ref-type="fig"}A). We silenced TFEB via specific short‐hairpin RNA (Fig [EV4](#embj201798250-fig-0004ev){ref-type="fig"}B and C), and the *in vitro* ECs' proliferation rate was evaluated by the count of 5‐ethynyl‐2′‐deoxyuridine (EdU)‐positive cells. The proliferative effect of fetal calf serum (FCS) and vascular endothelial growth factor‐A (VEGF‐A) was significantly impaired in TFEB‐silenced human ECs (sh‐TFEB ECs; Fig [2](#embj201798250-fig-0002){ref-type="fig"}C) and in ECs from lung of *Tfeb* ^iEC−/−^ mice (Fig [EV4](#embj201798250-fig-0004ev){ref-type="fig"}D). TFEB silencing in ECs specifically restrained the G~1~--S cycle transition, as assessed by propidium iodide staining (Fig [2](#embj201798250-fig-0002){ref-type="fig"}D). In sh‐TFEB ECs stimulated by VEGF‐A or FCS, we evidenced an increased percentage of cells blocked in the G1 phase and a decreased percentage of those progressing in S‐phase (Fig [2](#embj201798250-fig-0002){ref-type="fig"}D).

![TFEB expression and regulation in human ECs. Additional effects of *Tfeb* deletion on human ECs\
AmTOR inhibition activates TFEB nuclear translocation. Representative images of human ECs under basal conditions or after Torin stimulation (100 nM, 1 h) stained with anti‐TFEB Ab and DAPI (scale bars: 20 μm). Bar graphs indicate the percentage of TFEB positive nuclei versus total nuclei after Torin challenge (*n* = 3, mean ± SEM; \*\**P* \< 0.001 versus control cells by Student\'s *t‐*test).B, CCharacterization of TFEB shRNA (*n* = 3). (B) Western blot of TFEB in human ECs carrying five different commercial sh‐TFEB RNAs (1‐5) or the appropriate control (scr‐shRNA) transduced by pLKO lentivirus vector. (C) *TFEB* mRNA expression analyzed by qPCR in ECs carrying the different TFEB shRNAs (1‐5). Data are expressed as relative fold‐change compared with scr‐shRNA after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\*\**P* \< 0.0001 by Student\'s *t‐*test).D*TFEB* silencing reduced murine EC proliferation. Representative graph of lung ECs isolated from control and *Tfeb* ^iEC−/−^ mice ECs treated for 24 h with FCS (20%) or VEGF‐A (30 ng/ml). DNA incorporation of EdU was detected by flow cytometry. The percentage of proliferating cells is indicated (*n* = 4, mean ± SEM; \*\*\**P* \< 0.0001 versus ECs derived from control mice by Student\'s *t‐*test).E*TFEB* silencing does not affect human EC migration. Bar graph indicates the percentage of migrated sh‐TFEB and scr‐shRNA ECs stimulated with VEGF‐A (30 ng/ml, 5 h; *n* = 6, mean ± SEM, *P* = ns versus scr‐shRNA by Student\'s *t‐*test).\
Source data are available online for this figure.](EMBJ-38-e98250-g009){#embj201798250-fig-0004ev}

Then, we studied the effect of TFEB deletion on EC migration. An indirect *in vivo* evidence of EC motility is the analysis of filopodia, which characterize migrating cells. As shown in Fig [1](#embj201798250-fig-0001){ref-type="fig"}D, the number of filopodia at the front of retinal plexus was similar in control and in *Tfeb* ^*iEC*−/−^ mice, suggesting that Tfeb deletion did not affect EC motility. Accordingly, sh‐TFEB and scr‐shRNA ECs' *in vitro* chemotactic response to VEGF‐A was similar, suggesting that TFEB down‐regulation did not interfere with EC motility (Fig [EV4](#embj201798250-fig-0004ev){ref-type="fig"}E).

Finally, the effect of TFEB deletion was further examined in a morphogenetic assay. As shown in Fig [2](#embj201798250-fig-0002){ref-type="fig"}E, the absence of TFEB dampened ECs to form tube‐like structures on reduced growth factor Matrigel only after VEGF‐A stimulation.

TFEB modifies the transcriptional landscape in ECs {#embj201798250-sec-0007}
--------------------------------------------------

To describe the genetic program triggered by TFEB in ECs, we investigated the transcriptome modifications induced by TFEB silencing and the DNA promoter regions to which TFEB is recruited. The comparative transcriptome analysis of scr‐shRNA and sh‐TFEB ECs by LIMMA (Smyth, [2002](#embj201798250-bib-0064){ref-type="ref"}) defined a subset of 502 differentially expressed genes (DEGs; 133 up‐regulated and 369 down‐regulated, \|log~2~FC\|\> 0.5 and FDR \< 0.1; Fig [3](#embj201798250-fig-0003){ref-type="fig"}A). A volcano plot showed the changes in the log~2~ fold‐change and *P*‐values for all the genes in sh‐TFEB ECs compared to scr‐shRNA cells (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}A). The enriched biological functions of up‐ and down‐regulated genes were determined by DAVID analysis. In sh‐TFEB ECs, down‐regulated genes characterized processes related to "Cell Cycle", "Cell Division", "Mitotic cell cycle process", "G1/S transition of mitotic cell cycle", "DNA replication", and "DNA metabolic process". This result is consistent with the observation of the arrest of cell cycle and proliferation *in vivo* and *in vitro* after *Tfeb* silencing. On the other hand, up‐regulated gene enrichment was limited to "Positive regulation of protein catabolic process" and "Endocytosis" categories (Fig [3](#embj201798250-fig-0003){ref-type="fig"}B). Gene set Enrichment Analysis (GSEA) revealed the enrichment of the "negative regulation of cellular process", "negative regulation of proliferation", and "vesicle‐mediated transport" categories, supporting the DAVID analysis (Fig [3](#embj201798250-fig-0003){ref-type="fig"}C).

![TFEB gene regulation in human ECs\
Heatmap showing unsupervised hierarchical clustering of human differentially expressed genes between human scr‐shRNA and sh‐TFEB ECs. Red: up‐regulated genes; green: down‐regulated genes.Selection of enriched functional GO categories by DAVID analysis in differentially expressed genes between human sh‐TFEB and scr‐shRNA ECs. GO analyses were performed individually on down‐ or up‐regulated genes using DAVID tool (biological process). GO terms are ranked by *P*‐value corrected by Benjamini‐Hochberg method, and the number of genes is indicated.Selection enriched of Molecular Pathways by GSEA of microarray data comparing human sh‐TFEB and scr‐shRNA ECs. Normalized enrichment scores (NESs) and *P*‐values are reported.Selection of enriched functional GO categories by DAVID analysis on ChIP‐seq data set performed in human ECs overexpressing TFEBS142A. GO analyses were performed using DAVID tool (biological process). GO terms are ranked by *P*‐value corrected by BH method, and the number of genes is indicated.](EMBJ-38-e98250-g006){#embj201798250-fig-0003}

![TFEB gene regulation in human ECs\
AVolcano plots of human gene expression showing fold‐change and *P*‐value data comparing human sh‐TFEB and scr‐shRNA ECs. Red: up‐regulated genes; green: down‐regulated genes.BCharacterization of TFEBS142A overexpression in human ECs. Representative images of human ECs transduced with pTRIPZ‐TFEBS142A inducible lentivirus (scale bars: 20 μm) after transgene induction with doxycycline (0.5 μg/ml, 3 h; TFEBS142A) or not (control) and stained with anti‐TFEB Ab and DAPI. Bar graph indicates the quantity of cytosolic and nuclear TFEB as ratio between TFEBS142A and control ECs (*n* = 10, mean ± SEM, \*\**P* \< 0.0001 and \*\*\**P* \< 0.0001 by Student\'s *t‐*test).CRepresentative genomic view of the TFEB ChIP‐seq analysis. The TFEB ChIP‐seq plot shows distinct binding peaks with respect to the IgG ChIP‐seq.DComparison of the TFEB‐bound genomic regions with respect to the other indicated ChIP‐seq regions taken from the literature. TFEB correlates with open chromatin (DNAse) and with transcription factors known to be associated with active gene promoters (FOS, JUN, RNA PolII, MYC).EEnrichment of the E‐box DNA‐binding sequence of TFEB (CACGTG) on 70.9% of TFEB target genes in human ECs.FComparison of expression values in human ECs between TFEB‐bound and unbound genes. Box plots are median‐centered. The end of the box shows the upper and lower quartiles. The whiskers line shows the highest and lowest value excluding outliers.GDNA methylation analysis of the TFEB‐bound regions in human ECs using 450K Illumina microarray data from the literature (methylation status of 6,461 CpG has been analyzed).HGenomic localization of TFEB‐bound regions in human ECs.IGSEA analysis of TFEB‐bound genes comparing human sh‐TFEB and scr‐shRNA ECs microarray data. Enrichment plot shows modulated TFEB‐bound genes.J*TFEB* overexpression increased EC proliferation. Representative graph of control and TFEBS142A ECs treated for 24 h with FCS (20%). DNA incorporation of EdU was detected by flow cytometry. The percentage of proliferating cells is indicated (*n* = 4, mean ± SEM; \**P* \< 0.01 versus control ECs by Student\'s *t‐*test).K, L(K) qPCR and (L) immunoblots showing modulation of *CDK4* after TFEB overexpression in ECs. (K) Data are expressed as relative fold‐change compared with the expression in control cells after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\*\**P* \< 0.0001 by Student\'s *t‐*test). (L) Immunoblots of total lysates from control and TFEBS142A ECs probed with specific Abs. The bar graph shows the densitometric analysis expressed as % of CDK4 in TFEBS142A versus control ECs after the normalization with α‐tubulin (*n* = 3, mean ± SEM; \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).\
Source data are available online for this figure.](EMBJ-38-e98250-g011){#embj201798250-fig-0005ev}

To identify direct TFEB gene targets potentially supporting the transcriptional modulation described above, we performed chromatin immunoprecipitation sequencing (ChIP‐seq) in ECs overexpressing a TFEB mutant (S142A) protein, which is constitutively translocated to the nucleus and biologically active (Settembre *et al*, [2012](#embj201798250-bib-0059){ref-type="ref"}; Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}B).

TFEB ChIP‐seq showed several distinct binding events compared with IgG ChIP‐seq (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}C). TFEB binding regions on DNA correlated with open chromatin regions (DNAse) and with transcription factors known to be associated with active gene promoters (FOS, JUN, RNA PolII, MYC; Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}D).

In particular, we defined a set of 1,066 Ref/Seq protein‐coding genes showing strong TFEB binding enrichment on their core promoter. Of these, 71% contained the canonical TFEB binding sequence CACGTG (Palmieri *et al*, [2011](#embj201798250-bib-0044){ref-type="ref"}; Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}E).

Gene‐expression profiling of ECs revealed that TFEB was principally bound to highly expressed genes (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}F), at hypomethylated regions (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}G), and that almost 15% of the peaks (*P*‐value \< 10e^−8^) were located on gene promoters (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}H).

GSEA was used to investigate the correlation between the regulated genes and the list of TFEB‐bound genes. An enrichment plot showed that both up‐regulated and down‐regulated genes can be TFEB targets (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}I).

DAVID analysis on ChIP‐seq data set confirmed the known role of TFEB in lysosome/autophagic pathway but also underlined its involvement in cell cycle regulation, angiogenesis, blood vessel development, and morphogenesis (Fig [3](#embj201798250-fig-0003){ref-type="fig"}D). As shown in Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}L, the overexpression of TFEBS142A increased the proliferation of ECs as previously described for other cell types (Haq & Fisher, [2011](#embj201798250-bib-0024){ref-type="ref"}; Calcagnì *et al*, [2016](#embj201798250-bib-0005){ref-type="ref"}).

Taken together, these data support the *in vivo* and *in vitro* results showing that TFEB is involved in EC proliferation by regulating the expression of genes directly involved in the control of cell cycle.

The CDK4 gene is a direct target of TFEB {#embj201798250-sec-0008}
----------------------------------------

As evidenced by transcriptome analysis (Fig [4](#embj201798250-fig-0004){ref-type="fig"}A), qPCR (Fig [4](#embj201798250-fig-0004){ref-type="fig"}B), and immunoblotting analysis (Fig [4](#embj201798250-fig-0004){ref-type="fig"}C), TFEB silencing in human ECs negatively regulated the expression of genes involved in cell proliferation, including cyclin‐dependent kinase 4 (CDK4), cyclins (CCNA1, CCNA2), E2F transcription factors (E2F1, E2F2, E2F4), and their targets (MCM5, MCM6, CDC25B, CDCA4, CDCA7, PLK1, PCNA), which are involved in the control of S‐phase and mitosis. These data were further validated in murine lung ECs isolated from control and *Tfeb* ^iEC−/−^ mice (Fig [4](#embj201798250-fig-0004){ref-type="fig"}D). Therefore, we interrogated the ChIP‐seq data set to identify the direct TFEB targets within these modulated genes and we found that the promoter of CDK4 contains a binding site for TFEB (Fig [4](#embj201798250-fig-0004){ref-type="fig"}E).

![TFEB regulates cell cycle genes\
A--C(A) Heatmap, (B) qPCR, and (C) immunoblots showing the differentially expressed cell cycle‐related genes between scr‐shRNA and sh‐TFEB ECs. (A) Red: up‐regulated genes; green: down‐regulated genes. (B) Data are expressed as relative fold‐change compared with the expression in scr‐shRNA cells after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001 by Student\'s *t‐*test). (C) Immunoblots of total lysates from scr‐shRNA and sh‐TFEB ECs probed with specific Abs. The bar graph shows the densitometric analysis expressed as the ratio between the cell cycle genes and α‐tubulin (*n* = 3, mean ± SEM; \**P* \< 0.01, \*\**P* \< 0.001, and \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).DModulation of cell cycle genes expression in the lung ECs derived from control and *Tfeb* ^iEC−/−^ mice. Data are expressed as relative fold‐change compared with the expression in ECs of control mice after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001, by Student\'s *t‐*test).E--GAnalysis of TFEB binding and modulation of the *CDK4* promoter in human ECs. (E) Representative snapshot of TFEB binding on *CDK4* in human ECs. (F) ChIP was performed using digested chromatin from control ECs and TFEBS142A ECs incubated with IgG (indicated in the bar graph as "+IgG") or with Ab anti‐TFEB (indicated in the bar graph as "+Ab anti‐TFEB"), followed by qPCR for *CDK4*. Bar graph shows the percent enrichment (*n* = 3, mean ± SD). (G) Analysis of TFEB modulation of *CDK4* promoter in human ECs. Bar graph shows the relative luciferase activity % evaluated in control and TFEBS142A human ECs after transfection of *CDK4* full promoter and *CDK4* promoter deleted of TFEB binding site (*n* = 3, mean ± SEM; \**P* \< 0.01 and \*\**P* \< 0.001 by Student\'s *t‐*test).HModulation of Rb protein in sh‐TFEB ECs. Immunoblots of total lysates from scr‐shRNA and sh‐TFEB ECs probed with phospho‐Rb and total Rb Abs. The bar graph shows the densitometric analysis of the immunoblotting expressed as % of sh‐TFEB versus scr‐shRNA and the ratio between phospho‐Rb and total Rb in the different conditions (*n* = 3, mean ± SEM; \*\**P* \< 0.001, \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).\
Source data are available online for this figure.](EMBJ-38-e98250-g008){#embj201798250-fig-0004}

To further confirm the direct activity of TFEB on CDK4 expression, ChIP and promoter‐luciferase assay were performed. As shown in Fig [4](#embj201798250-fig-0004){ref-type="fig"}F, the chromatin immunoprecipitated with an antibody anti‐TFEB contained the *CDK4* promoter identified by PCR using two CDK4‐specific primers. We further investigated the *CDK4* promoter activity by luciferase reporter assay in ECs overexpressing TFEBS142A, an active constitutive variant that localizes preferentially in the nucleus (Settembre *et al*, [2012](#embj201798250-bib-0059){ref-type="ref"}). TFEBS142A‐carrying luciferase reporter vectors respectively containing CDK4 full‐length promoter and a deleted form lacking 100 bps encompassing the putative TFEB binding site were analyzed. TFEBS142A overexpression resulted in a significant increase in *CDK4* promoter activity, which was completely blunted by the deletion of TFEB binding site (Fig [4](#embj201798250-fig-0004){ref-type="fig"}G). The activation of *CDK4* promoter activity was also related to the increase in CDK4 transcription and protein expression (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}K and L). One of the most important substrates of CDK4 is retinoblastoma (Rb) protein, which associates with E2F transcription factor in quiescent cells. When cells progress in G1 phase, CDK4 phosphorylates Rb, allowing the release of E2F, which migrates into the nucleus and activates the transcription of genes required for S‐phase (Malumbres & Barbacid, [2009](#embj201798250-bib-0037){ref-type="ref"}). Transcriptomic analysis of sh‐TFEB ECs did not indicate Rb as a DEG and immunoblotting analysis showed that its expression was not altered by TFEB silencing (Fig [4](#embj201798250-fig-0004){ref-type="fig"}H). On the contrary, we evidenced in sh‐TFEB ECs a down‐regulation of phospho‐Rb (Fig [4](#embj201798250-fig-0004){ref-type="fig"}H), which paralleled the reduced expression of CDK4 (Fig [4](#embj201798250-fig-0004){ref-type="fig"}B and C).

These data support the rationale that CDK4‐Rb‐E2F axis is a target of TFEB in ECs and suggest that its impairment could explain the *in vivo* alteration of vascular development described in *Tfeb* ^iEC−/−^ mice.

VEGFR2 gene is an indirect target gene of TFEB in ECs {#embj201798250-sec-0009}
-----------------------------------------------------

The above considerations stimulated us to study other possible mechanisms sustaining the vascular phenotype. We investigated a possible role for VEGF‐A/VEGFR2 pathway, which is definitely a key machinery involved in EC migration, proliferation, and morphogenesis (Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}). We were also intrigued by the observation that full *Tfeb* ^−/−^ mice exhibited a reduced placenta expression of VEGF‐A (Steingrímsson *et al*, [1998](#embj201798250-bib-0065){ref-type="ref"}). Furthermore, while the reduced transcription of *CDK4* in sh‐TFEB ECs could justify the observed proliferative block, this defect was not necessarily accountable for the morphogenetic alterations observed *in vivo* (Fig [1](#embj201798250-fig-0001){ref-type="fig"}D) and *in vitro* in the Matrigel morphogenetic assay (Fig [2](#embj201798250-fig-0002){ref-type="fig"}E), which is independent from the proliferation even in the presence of VEGF‐A (Serini *et al*, [2003](#embj201798250-bib-0057){ref-type="ref"}).

For these reasons, we investigated whether TFEB deletion could interfere on VEGFR2 expression. The expression of *Vegfr2* was increased in the vessels of *Tfeb* ^EC−/−^ embryos (E10.5; Fig [5](#embj201798250-fig-0005){ref-type="fig"}A) and of retina and kidney of *Tfeb* ^iEC−/−^ mice compared with that in control mice (Fig [5](#embj201798250-fig-0005){ref-type="fig"}B and C). Since neural cells (Robinson *et al*, [2001](#embj201798250-bib-0052){ref-type="ref"}) and podocytes (Bartlett *et al*, [2016](#embj201798250-bib-0003){ref-type="ref"}) both express *Vegfr2,* we examined the amount of receptor co‐localized with the specific endothelial markers iB4 or CD31 in retina and kidney and confirmed the increased level of the receptor in the ECs of *Tfeb* ^iEC−/−^ mice (Fig [5](#embj201798250-fig-0005){ref-type="fig"}B and C).

![Regulation of VEGFR2 by TFEB in ECs\
A--CIncrease in *Vegfr2* expression in the vasculature of *Tfeb* ^EC−/−^ and *Tfeb* ^iEC−/−^ mice. (A) Representative immunostaining images of *Tfeb* ^EC−/−^ embryonic vessels (E10.5) stained with anti‐endomucin and anti‐Vegfr2 Abs (scale bars: 50 μm). Bar graph indicates the Vegfr2 mean intensity only in endomucin^+^ vessel areas (embryos *n* = 6, mean ± SEM; \*\*\**P* \< 0.0001 versus control embryos by Student\'s *t‐*test). (B) Representative immunostaining images (i) and detail (ii) of the vascular front and vascular plexus of the retina (p5) of control and *Tfeb* ^iEC−/−^ mice with anti‐iB4 and anti‐Vegfr2 Abs (scale bars: 50 μm). Bar graph indicates the Vegfr2 mean intensity only in iB4^+^ vessel areas (mice *n* = 6, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001 versus control mice by Student\'s *t‐*test). (C) Representative immunostaining images of the glomerulus (p17) of control and *Tfeb* ^iEC−/−^ mice with anti‐podocin, anti‐CD31, and anti‐Vegfr2 Abs (scale bars: 50 μm). Bar graphs indicate the Vegfr2 mean intensity in CD31^+^ vessel areas (mice *n* = 6, mean ± SEM; \*\**P* \< 0.001 versus control mice by Student\'s *t‐*test).D--F*VEGFR2* expression is regulated by TFEB. (D, E) qPCR of VEGFR2 in lung ECs obtained from control and *Tfeb* ^iEC−/−^ mice (D) and in human sh‐TFEB (E). Data are expressed as relative fold‐change compared with the expression in control cells after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001, by Student\'s *t‐*test). (F) Immunoblots of total lysates from scr‐shRNA and sh‐TFEB ECs probed with anti‐VEGFR2 and α‐tubulin Abs. The bar graph shows the densitometric analysis expressed as the ratio between VEGFR2 and α‐tubulin (*n* = 3, mean ± SEM; \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).GAnalysis of TFEB binding to the *VEGFR2* promoter in human ECs. ChIP was performed using digested chromatin from human control ECs and TFEBS142A ECs incubated with IgG (indicated in the bar graph as "+IgG") or with Ab anti‐TFEB (indicated in the bar graph as "+Ab anti‐TFEB"), followed by qPCR for *VEGFR2*. Bar graph shows the percent enrichment (*n* = 3, mean ± SD).\
Source data are available online for this figure.](EMBJ-38-e98250-g010){#embj201798250-fig-0005}

Transcriptome data validated by qPCR (Fig [5](#embj201798250-fig-0005){ref-type="fig"}D and E) and immunoblotting (Fig [5](#embj201798250-fig-0005){ref-type="fig"}F) showed the up‐regulation of VEGFR2 in murine lung ECs isolated from *Tfeb* ^iEC−/−^ mice and sh‐TFEB ECs. However, this transcriptional effect is independent from a direct binding of TFEB on *VEGFR2* promoter, as demonstrated by ChIP‐seq (not shown) and ChIP‐qPCR (Fig [5](#embj201798250-fig-0005){ref-type="fig"}G) performed in sh‐TFEB ECs.

In sh‐TFEB ECs, the analysis of VEGFR2 localization by FACS (Fig [6](#embj201798250-fig-0006){ref-type="fig"}A), total internal reflection fluorescence (TIRF) microscopy (Fig [6](#embj201798250-fig-0006){ref-type="fig"}B), and biotinylation of endothelial plasma membrane (PM; Napione *et al*, [2012a](#embj201798250-bib-0042){ref-type="ref"}a; Fig [6](#embj201798250-fig-0006){ref-type="fig"}C) indicated a strong accumulation of the receptor at the PM. To rescue the effect of TFEB down‐modulation, ECs were co‐infected with sh‐TFEB and pTRIPZ‐TFEBS142A vectors without an evident effect (not shown). This negative result could be explained by the fact that TFEB overexpression (Fig [EV5](#embj201798250-fig-0005ev){ref-type="fig"}) targeted a wide number of genes. Therefore, the overexpression of exogenous TFEB could activate molecules that mask the expected modification of VEGFR2 and other specific TFEB targets identified by loss‐of‐function strategy.

![Role of TFEB in regulating VEGFR2 localization and activity in human ECs\
A, BSilenced *TFEB* alters the localization of VEGFR2. (A) FACS analysis of surface VEGFR2 expression on human scr‐shRNA and sh‐TFEB ECs. Bar graph shows the ratio between total and PM VEGFR2 (*n* = 6, mean ± SEM; \*\**P* \< 0.001 versus scr‐shRNA by Student\'s *t‐*test). (B) Representative TIRF and epifluorescence images of human scr‐shRNA and sh‐TFEB ECs after staining with anti‐VEGFR2 Ab (scale bars: 10 μm). Bar graphs show the ratio of VEGFR2 analyzed in epifluorescence and TIRF mode analyzed by TIRF (*n* = 40, mean ± SEM; \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).CSilenced *TFEB* alters the localization and the phosphorylation state of VEGFR2 and its signal transduction. Representative immunoblot of PM biotinylated portion and total cell lysates of scr‐shRNA and sh‐TFEB ECs after VEGF‐A stimulation (30 ng/ml). Blots of total or PM cell lysates were probed with anti‐VEGFR2. Blots of total cell lysates were probed with anti‐p‐Y1175‐VEGFR2, anti‐PLCγ, p‐PLCγ, anti‐ERK‐1/2, anti‐pERK1/2, anti‐p‐Src, anti‐Src, anti‐CD31, and α‐tubulin Abs. The bar graphs (i,ii) show densitometric analysis of stimulated versus unstimulated scr‐shRNA and sh‐TFEB ECs expressed as: (i) % of VEGFR2 on PM fraction (*n* = 3, mean ± SEM; ANOVA *P* \< 0.02; \*\**P* \< 0.001 versus scr‐shRNA by Bonferroni post‐test), (ii) % of VEGFR2 total (*n* = 3, mean ± SEM; ANOVA *P* \> 0.05; \**P* \< 0.05 and \*\**P* \< 0.001 versus scr‐shRNA by Bonferroni post‐test).D, ERegulation of autophagy and lysosome pathway by TFEB silencing. (D) qPCR and (E) immunoblots showing the differentially expressed autophagy‐ and lysosome‐related genes between human scr‐shRNA and sh‐TFEB ECs. (D) Data are expressed as relative fold‐change compared with the expression in control cells after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\*\**P* \< 0.0001 by Student\'s *t‐*test). (E) Immunoblots of total lysates from human scr‐shRNA and sh‐TFEB ECs probed with anti‐ULK‐1, anti‐ATG9, anti‐LC3‐I/II, anti‐LAMP‐1, and α‐tubulin Abs. The bar graph shows the densitometric analysis expressed as the ratio between scr‐shRNA and sh‐TFEB ECs (*n* = 3, mean ± SEM; \*\**P* \< 0.001, \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).F*TFEB* silencing inhibits VEGFR2 internalization. Bar graphs of VEGFR2 internalization expressed as the percent of internalized VEGFR2 versus PM VEGFR2 after VEGF‐A stimulation (*n* = 6, mean ± SEM, ANOVA *P* \< 0.0001; \*\*\**P* \< 0.0001 versus scr‐shRNA by Bonferroni post‐test).\
Source data are available online for this figure.](EMBJ-38-e98250-g012){#embj201798250-fig-0006}

In the absence of a direct effect of TFEB on *VEGFR2* transcription (Fig [5](#embj201798250-fig-0005){ref-type="fig"}G), we hypothesized that the altered expression of VEGFR2 and its increased localization on PM might be the result of the combined activity of an altered membrane trafficking and a miR‐dependent post‐transcriptional mechanism.

TFEB deletion alters VEGFR‐2 membrane trafficking {#embj201798250-sec-0010}
-------------------------------------------------

On the basis of the described results, we investigated whether the accumulation of VEGFR2 in PM (Fig [6](#embj201798250-fig-0006){ref-type="fig"}A--C) could be related to a specific TFEB‐mediated mechanism orchestrating the VEGFR2 membrane trafficking (Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}).

Actually, TFEB deletion negatively modulated the genetic program sustaining lysosome biogenesis, autophagy, vesicles trafficking, and exocytosis (Medina *et al*, [2011](#embj201798250-bib-0041){ref-type="ref"}; Napolitano & Ballabio, [2016](#embj201798250-bib-0043){ref-type="ref"}; Raben & Puertollano, [2016](#embj201798250-bib-0050){ref-type="ref"}) in many cell types including ECs (Lu *et al*, [2017](#embj201798250-bib-0036){ref-type="ref"}). Transcriptomic analysis indicated that the expression of some genes characterized by the presence of the coordinated lysosomal expression and regulation (CLEAR) element (Palmieri *et al*, [2011](#embj201798250-bib-0044){ref-type="ref"}) were modified in sh‐TFEB ECs (DEGs down‐regulated: ATP6V0D1, CLCN7, CTSB; DEGs up‐regulated: RRAG). Similarly, TFEB silencing reduced markers of autophagic flux. In particular, the ratio between microtubule‐associated proteins 1A/1B light chain (LC) 3‐II and LC3‐I, and the expression of Unc‐51 like autophagy activating kinase (ULK‐1; Martina *et al*, [2012](#embj201798250-bib-0039){ref-type="ref"}; Settembre *et al*, [2012](#embj201798250-bib-0059){ref-type="ref"}) and autophagy‐related gene (ATG)9A (Roa *et al*, [2008](#embj201798250-bib-0051){ref-type="ref"}) were reduced in sh‐TFEB ECs (Fig [6](#embj201798250-fig-0006){ref-type="fig"}D and E).

Because lysosomal and autophagy pathways are interconnected with endosomal system (Pavel & Rubinsztein, [2017](#embj201798250-bib-0046){ref-type="ref"}), we analyzed the dynamics of VEGFR2 trafficking in sh‐TFEB ECs. Whereas PM VEGFR2 started to decrease immediately after VEGF‐A challenge in scr‐shRNA ECs (\~30% reduction after 5 min), knocking down TFEB consistently altered VEGFR2 PM clearance that was slower (\~20% reduction) and started only after 10 min from stimulus. Concomitantly, the reduction of total amount of VEGFR2, correlated with its degradation, in scr‐shRNA ECs became evident after 5 min of VEGF‐A challenge (\~14% versus unstimulated ECs), while this drop was evident later (10 min) in sh‐TFEB ECs (\~17% versus unstimulated ECs; Fig [6](#embj201798250-fig-0006){ref-type="fig"}C).

The perturbing effect of TFEB silencing was further analyzed by studying the co‐localization of VEGFR2 with caveolin‐1 (CAV‐1)‐rich membrane rafts, which represent specific domains that favor the signaling properties of the receptor (Labrecque *et al*, [2003](#embj201798250-bib-0032){ref-type="ref"}; Cho *et al*, [2004](#embj201798250-bib-0010){ref-type="ref"}). As inferred from co‐localization analysis, TFEB silencing did not significantly alter the expression and localization of CAV‐1 on the PM, but interestingly, it modified the spatial relationship between VEGFR2 and CAV‐1. sh‐TFEB ECs exhibited an approximately 25% reduction in CAV‐1‐associated VEGFR2 compared with scr‐shRNA ECs ([Appendix Fig S1B](#embj201798250-sup-0009){ref-type="supplementary-material"}).

The effect of TFEB silencing on VEGFR2 distribution was further evaluated by the specific quantification of receptor endocytosis by a receptor internalization assay (Valdembri *et al*, [2009](#embj201798250-bib-0069){ref-type="ref"}). TFEB silencing moderately but significantly altered VEGFR2 internalization time‐course. Whereas VEGFR2 internalization started immediately (5 min) after VEGF‐A challenge in control cells (\~12% versus unstimulated ECs), a 10‐min delay was seen in sh‐TFEB ECs suggesting an impairment of internalization process (\~5% versus unstimulated ECs, *P* = ns after 5 min of VEGF‐A incubation and \~7% versus unstimulated ECs, *P* \< 0.01 after 10 min of VEGF‐A incubation; Fig [6](#embj201798250-fig-0006){ref-type="fig"}F). The inhibition of internalization of VEGFR2 in sh‐TFEB ECs was confirmed by the reduction of co‐localization with Rab5^+^ endosomes after VEGF‐A stimulation ([Appendix Fig S1C](#embj201798250-sup-0009){ref-type="supplementary-material"}).

Because VEGFR2 exocytosis from endosomal compartment to PM participates to properly maintain its signaling properties (Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}), we investigated the co‐localization of the receptor with the Golgi marker Trans‐Golgi Network 46 (TGN46) and Rab4^+^ exocytic vesicles (Jopling *et al*, [2014](#embj201798250-bib-0029){ref-type="ref"}). TFEB silencing did not modify the amount of VEGFR2 localized in Golgi compartment ([Appendix Fig S1D](#embj201798250-sup-0009){ref-type="supplementary-material"}), but increased that accumulated in Rab4^+^ vesicles (170.2 ± 9% compared to scr‐shRNA ECs; *n* = 4, *P* \< 0.01; [Appendix Fig S2E](#embj201798250-sup-0009){ref-type="supplementary-material"}).

These observations prompted us to interrogate the enriched gene set belonging to the Gene Ontology "protein targeting to membrane" in TFEB‐silenced ECs to identify a mechanism responsible for the observed accumulation of VEGFR2 in the PM.

Within the modulated genes (ADORA1, ARL6, CACNB1, ICMT, ATG3, SDCBP, SEC63, ATG4C, MGEA5, MICALL1, MYO1C, TAOK2, NCF1, PRKCI), we focused our attention on myosin 1c (MYO1C), which was involved in VEGFR2 exocytosis (Tiwari *et al*, [2013](#embj201798250-bib-0068){ref-type="ref"}). ChIP‐seq (Fig [7](#embj201798250-fig-0007){ref-type="fig"}A) and ChIP‐qPCR (Fig [7](#embj201798250-fig-0007){ref-type="fig"}B) indicated that TFEB can bind to the *MYO1C* promoter. ECs overexpressing *TFEBS142A* showed reduced activation of *MYO1C* promoter ([Appendix Fig S2A](#embj201798250-sup-0009){ref-type="supplementary-material"}) and consequently a decreased transcription ([Appendix Fig S2B](#embj201798250-sup-0009){ref-type="supplementary-material"}). On the contrary, in sh‐TFEB ECs MYO1C was up‐regulated (Fig [7](#embj201798250-fig-0007){ref-type="fig"}C and D). This phenotype was also observed in the vasculature of retina (p5) and kidney (p17) of *Tfeb* ^iEC−/−^ mice (Fig [7](#embj201798250-fig-0007){ref-type="fig"}E and F).

![Role of MYO1C in the localization of VEGFR2 in *TFEB*‐silenced ECs\
A--CAnalysis of TFEB binding and modulation of the *MYO1C* promoter in human ECs. (A) Representative snapshot of TFEB binding on *MYO1C* in human ECs. (B) ChIP was performed using digested chromatin from control ECs and TFEBS142A ECs incubated with IgG (indicated in the bar graph as "+IgG") or with Ab anti‐TFEB (indicated in the bar graph as "+Ab anti‐TFEB"), followed by qPCR for *MYO1C*. Bar graph shows the percent enrichment (*n* = 3, mean ± SD). (C) qPCR of *MYO1C* expression in scr‐shRNA, sh‐TFEB, sh‐MYO1C, and sh‐TFEB+sh‐MYO1C ECs. Data are expressed as relative fold‐change compared with the expression in scr‐shRNA ECs after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001 by Student\'s *t‐*test).D*MYO1C* silencing reverses the effect of *TFEB* silencing on the up‐regulation of PM VEGFR2. Analyses were performed on human ECs carrying appropriate scr‐shRNA or sh‐TFEB in the presence or absence of sh‐MYO1C. Representative Western blot of MYOC1, total and PM biotinylated VEGFR2 (representative experiment out of 4 with similar results).E, FRepresentative immunostaining images of the vascular plexus of the retina (p5) (E) and glomerulus (p17) (F) of control and *Tfeb* ^iEC−/−^ mice with anti‐CD31 and anti‐MYO1C Abs (scale bars: 50 μm). Bar graphs indicate the Myo1C mean intensity only in vessel areas CD31^+^ (*n* = 6, mean ± SEM; \*\*\**P* \< 0.0001 versus control mice by Student\'s *t‐*test).GRepresentative TIRF and epifluorescence images of VEGFR2 in scr‐shRNA, sh‐TFEB, sh‐MYO1C, and sh‐TFEB+sh‐MYO1C human ECs (scale bars: 10 μm). Bar graph shows the ratio between PM and total VEGFR2 (*n* = 40, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001 versus scr‐shRNA by Student\'s *t‐*test).\
Source data are available online for this figure.](EMBJ-38-e98250-g013){#embj201798250-fig-0007}

Interestingly, MYO1C‐silencing ([Appendix Fig S2C and D](#embj201798250-sup-0009){ref-type="supplementary-material"}) decreased the amount of VEGFR2 co‐localized with Rab4^+^ vesicles ([Appendix Fig S2E](#embj201798250-sup-0009){ref-type="supplementary-material"}). These data suggested that MYO1C deletion reduces the transport of the receptor to Rab4^+^ endosomes involved in its exocytosis. This result matches the observation that MYO1C silencing in sh‐TFEB ECs reduced specifically the amount of PM VEGFR2, as demonstrated by immunoblotting (Fig [7](#embj201798250-fig-0007){ref-type="fig"}D), the ratio of the VEGFR2 signal recorded in TIRF and epifluorescence modes (Fig [7](#embj201798250-fig-0007){ref-type="fig"}G), and the ratio of VEGFR2 on the PM to total expression measured by FACS ([Appendix Fig S2F](#embj201798250-sup-0009){ref-type="supplementary-material"}).

On the contrary, MYO1C silencing both in scr‐shRNA and in sh‐TFEB ECs did not affect VEGFR2 transcription ([Appendix Fig S2G](#embj201798250-sup-0009){ref-type="supplementary-material"}), total protein expression (Fig [7](#embj201798250-fig-0007){ref-type="fig"}D; densitometric analysis as % of scr‐shRNA: 220.7 ± 5.2% in sh‐TFEB ECs *P* \< 0.0001; 114.7 ± 7.7% in sh‐MYO1C *P* = ns; 230.3 ± 3.7% in sh‐TFEB+sh‐MYO1C ECs *P* \< 0.0001, *n* = 3), and receptor internalization ([Appendix Fig S2H](#embj201798250-sup-0009){ref-type="supplementary-material"}).

The inhibitory effect of TFEB deletion on ECs proliferation was not counteracted by MYO1C silencing in human ECs ([Appendix Fig S2I](#embj201798250-sup-0009){ref-type="supplementary-material"}). This result is not surprising in view of the deep influence of TFEB on genes related to cell proliferation (Fig [3](#embj201798250-fig-0003){ref-type="fig"}B and C).

TFEB deletion up‐regulates VEGFR2 by inhibiting a miR‐15a/16‐1‐dependent post‐transcriptional regulatory mechanism {#embj201798250-sec-0011}
------------------------------------------------------------------------------------------------------------------

Because TFEB silencing up‐regulated VEGFR2 mRNA independently from a direct action on the promoter (Fig [5](#embj201798250-fig-0005){ref-type="fig"}G), we further speculated a role for a miR‐dependent post‐transcriptional mechanism (Cora' *et al*, [2017](#embj201798250-bib-0011){ref-type="ref"}), which is widely involved in the control of vascular functions, including VEGFR2 (Chamorro‐Jorganes *et al*, [2013](#embj201798250-bib-0008){ref-type="ref"}; Dang *et al*, [2013](#embj201798250-bib-0012){ref-type="ref"}; Park *et al*, [2013](#embj201798250-bib-0045){ref-type="ref"}).

By crossing data of literature about the genomic location of miRs (Chamorro‐Jorganes *et al*, [2013](#embj201798250-bib-0008){ref-type="ref"}; Dang *et al*, [2013](#embj201798250-bib-0012){ref-type="ref"}) directly involved in the angiogenic process ([Appendix Fig S3A](#embj201798250-sup-0009){ref-type="supplementary-material"}) with our ChIP‐seq data set, we identified the "structural maintenance of chromosome 4" (SMC4) and the "deleted in leukemia‐2" (DLEU2) genes ([Appendix Fig S3A](#embj201798250-sup-0009){ref-type="supplementary-material"}) as two putative miR host genes involved in VEGFR2 regulation by TFEB. ChIP‐seq and ChIP‐qPCR indicated that TFEB bound to the *DLEU2* but not the *SMC4* promoter (Fig [8](#embj201798250-fig-0008){ref-type="fig"}A). For these reasons, we focused on *DLEU2*, which is a tumor suppressor gene that is lost early in chronic lymphatic leukemia (Klein *et al*, [2010](#embj201798250-bib-0031){ref-type="ref"}). *DLEU2* encodes a sterile transcript as well as the miR‐15a/16‐1 cluster, which is located intronic to the gene. This cluster encodes mature miR‐15a‐3p/5p and miR‐16‐1‐3p/5p (Yue & Tigyi, [2010](#embj201798250-bib-0073){ref-type="ref"}), which regulate the cell cycle and apoptosis and influence vascular function (Sun *et al*, [2013](#embj201798250-bib-0066){ref-type="ref"}; Jackstadt & Hermeking, [2015](#embj201798250-bib-0027){ref-type="ref"}), including VEGFR2 expression (Chamorro‐Jorganes *et al*, [2011](#embj201798250-bib-0007){ref-type="ref"}; Chan *et al*, [2013](#embj201798250-bib-0009){ref-type="ref"}).

![Indirect regulation of VEGFR2 via miR‐15a/16 by TFEB in ECs\
AAnalysis of TFEB binding to *DLEU2* and *SMC4* promoters in human ECs. ChIP was performed using digested chromatin from control ECs and TFEBS142A ECs incubated with IgG (indicated in the bar graph as "+IgG") or with Ab anti‐TFEB (indicated in the bar graph as "+Ab anti‐TFEB"), followed by qPCR for *DLEU2 and SMC4*. Bar graph shows the percent enrichment (*n* = 3, mean ± SD).B*DLEU2* expression is regulated by TFEB. qPCR of *DLEU2* in human scr‐shRNA, sh‐TFEB, or control and TFEBS142A ECs (left panel) and lung ECs obtained from control and *Tfeb* ^iEC−/−^ mice (right panel). Data are expressed as relative fold‐change compared with the expression in scr‐shRNA and control cells after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \**P* \< 0.01, and \*\*\**P* \< 0.0001 by Student\'s *t‐*test).CHuman miR‐15a‐5p and miR‐16‐5p are regulated by TFEB. qPCR of miR‐15a‐5p (left panel) and miR‐16‐5p (right panel) in sh‐TFEB or TFEBS142A ECs. Data are expressed as relative fold‐change compared with the expression in scr‐shRNA and control cells after normalization to the housekeeping gene RNU44 (*n* = 3, mean ± SEM; \*\*\**P* \< 0.0001 by Student\'s *t‐*test).D--GVEGFR2 expression is regulated by TFEB through a miR‐dependent mechanism. (D, F) qPCR of VEGFR2 in human scr‐shRNA and sh‐TFEB ECs (D, E) and in control and TFEBS142A ECs (F, G) treated with a specific miR‐control, miR‐15a‐5p, and miR‐16‐5p mimics or inhibitors. (D, F) Data are expressed as relative fold‐change compared with the expression in control cells after normalization to the housekeeping gene TBP (*n* = 3, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001 versus control or scr‐shRNA plus miR‐control and ^\#\#^ *P* \< 0.001 and ^\#\#^ *P* \< 0.0001 versus sh‐TFEB and TFEBS142A plus miR‐control by Student\'s *t‐*test). (E, G) Representative Western blot of VEGFR2 expression under the same experimental conditions previously reported. The bar graph shows the densitometric analysis expressed as the ratio between VEGFR2 and α‐tubulin (*n* = 3, mean ± SEM; \*\**P* \< 0.001 and \*\*\**P* \< 0.0001 versus control or scr‐shRNA plus miR‐control and ^\#^ *P* \< 0.01 and ^\#\#^ *P* \< 0.001 versus sh‐TFEB and TFEBS142A plus miR‐control by Student\'s *t‐*test).\
Source data are available online for this figure.](EMBJ-38-e98250-g014){#embj201798250-fig-0008}

DLEU2 was down‐ and up‐regulated in sh‐TFEB and TFEBS142A ECs, respectively (Fig [8](#embj201798250-fig-0008){ref-type="fig"}B). The deletion of *Tfeb* resulted also in the down‐modulation of *Dleu2* in lung ECs isolated from mutant mice (Fig [8](#embj201798250-fig-0008){ref-type="fig"}B).

Next, we analyzed the expression of isoforms of the miR‐15a/16‐1 cluster in ECs (Fig [8](#embj201798250-fig-0008){ref-type="fig"}C, [Appendix Fig S3B](#embj201798250-sup-0009){ref-type="supplementary-material"}). miR‐15a‐5p and miR‐16‐5p were expressed at high levels, whereas miR‐15a‐3p and miR‐16‐1‐3p levels were negligible and were therefore not considered further.

In parallel with *DLEU2*, miR‐15a‐5p and miR‐16‐5p were down‐ and up‐regulated in sh‐TFEB and TFEBS142A ECs, respectively (Fig [8](#embj201798250-fig-0008){ref-type="fig"}C). Similarly, the *in vitro* Cre‐mediated *Tfeb* deletion resulted in a marked reduction of miR‐15a‐5p and miR‐16‐5p in lung ECs isolated from mutant mice ([Appendix Fig S3B](#embj201798250-sup-0009){ref-type="supplementary-material"}).

The functional connection between DLEU2 and the intragenic mir‐15a‐5p and mir‐16‐5p was further validated in sh‐DLEU2 ECs ([Appendix Fig S3C](#embj201798250-sup-0009){ref-type="supplementary-material"}), in which expression of TFEBS142A was unable to increase their expression. In particular, the fold‐change expression of mir‐15a‐5p and mir‐16‐5p was respectively increased of 2.8 ± 0.6 and 4.8 ± 0.7 in ECs carrying TFEBS142A compared to control cells (*n* = 3, *P* \< 0.0001). The co‐expression of sh‐DLEU2 and the constitutively active TFEB mutant blocked the expression of both miRs (mir‐15a‐5p: 0.2 ± 0.2 relative fold‐change; and mir‐16‐5p: 0.4 ± 0.2 relative fold‐change *n* = 3, *P* \< 0.0001 versus TFEBS142A ECs).

To determine the possible regulatory role for miR‐15a‐5p and miR‐16‐5p in *VEGFR2* expression, we employed gain‐ and loss‐of‐function approaches.

The up‐regulation of VEGFR2 transcription and protein synthesis observed in sh‐TFEB ECs was rescued by transducing the specific mimic of miR‐15a‐5p and miR‐16‐5p (Fig [8](#embj201798250-fig-0008){ref-type="fig"}D and E). On the contrary, the down‐regulation of VEGFR2 transcription and protein synthesis observed in TFEBS142A ECs was rescued by transduction of the specific inhibitors of miR‐15a‐5p and miR‐16‐5p (Fig [8](#embj201798250-fig-0008){ref-type="fig"}F and G).

These data suggest a direct role for these miRs in the regulation of *VEGFR2* by TFEB.

On the contrary in sh‐TFEB ECs, the rescue of the level of VEGFR2 similar to that presented in scr‐shRNA ECs was not able to overcome the reduced proliferation stimulated by VEGF‐A ([Appendix Fig S3D](#embj201798250-sup-0009){ref-type="supplementary-material"}), in agreement with the direct effect of TFEB on CDK4 (Figs [4](#embj201798250-fig-0004){ref-type="fig"}A--F and [EV5](#embj201798250-fig-0005ev){ref-type="fig"}K and L).

VEGFR2 signal is reduced in TFEB‐silenced ECs {#embj201798250-sec-0012}
---------------------------------------------

The above‐described alterations of VEGFR2 behavior in sh‐TFEB ECs prompted us to investigate its signaling properties by analyzing VEGFR2 phosphorylation at Y1175 in total lysates, which is a discrete docking site for PLCγ and one of the most important effector of activated VEGFR2 (Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}). In sh‐TFEB ECs compared with control cells, the degree of receptor phosphorylation after VEGF‐A challenge was smaller relative to the larger amount of total VEGFR2 (Fig [6](#embj201798250-fig-0006){ref-type="fig"}C, [Appendix Fig S1A](#embj201798250-sup-0009){ref-type="supplementary-material"}). We also observed a concomitant decrease in the phosphorylation of PLCγ and ERK‐1/2, which are implicated in EC proliferation in response to VEGF‐A (Takahashi *et al*, [2001](#embj201798250-bib-0507){ref-type="ref"})) (Fig [6](#embj201798250-fig-0006){ref-type="fig"}C, [Appendix Fig S1A](#embj201798250-sup-0009){ref-type="supplementary-material"}). The activation of c‐Src, another tyrosine kinase substrate of VEGFR2 involved in cytoskeletal rearrangements and cell‐matrix adhesion (Ferrando *et al*, [2012](#embj201798250-bib-0019){ref-type="ref"}; Fig [6](#embj201798250-fig-0006){ref-type="fig"}C, [Appendix Fig S1A](#embj201798250-sup-0009){ref-type="supplementary-material"}), was reduced in sh‐TFEB challenged with VEGF‐A.

These data indicate that the altered mRNA dynamics connected with a defect of receptor trafficking result in a reduced function of VEGFR2 in ECs lacking TFEB.

Discussion {#embj201798250-sec-0013}
==========

Here, we demonstrate that the EC‐targeted deletion of Tfeb alters the mid‐ and late phase of vascular development in mouse. By combining gene expression and ChIP‐seq analyses in genetically modified ECs where TFEB is either silenced or overexpressed, we found that this transcription factor positively regulates the expression of *CDK4* and miR‐15a/16‐1 cluster, while it exerts a repressor activity on *MYO1C*. The absence of TFEB results in a reduction of CDK4 and the consequent block of cell cycle in ECs. At the same time, we found that VEGFR2 trafficking and its compartment localization is profoundly modified. Such alterations are mediated by the up‐regulation of *MYO1C* and the abrogation of miR‐15a/16‐1‐mediated post‐transcriptional control of VEGFR2 expression, respectively. While the abnormal VEGFR2 behavior could be a potential compensation mechanism with respect to the cell cycle hindrance, we demonstrated that the overall signaling activity is impaired.

The effect of TFEB on cell proliferation has been extensively investigated and primarily connected with its effect on autophagic flux. Knockdown of TFEB decreased proliferation of prostate (Blessing *et al*, [2017](#embj201798250-bib-0004){ref-type="ref"}) and pancreatic cancer cell lines (Perera *et al*, [2015](#embj201798250-bib-0047){ref-type="ref"}). On the contrary, TFEB up‐regulation in renal and in cancer cells resulted in an increased proliferation rate (Calcagnì *et al*, [2016](#embj201798250-bib-0005){ref-type="ref"}; Di Malta *et al*, [2017](#embj201798250-bib-0013){ref-type="ref"}). The necessary role of TFEB in cell growth is further indirectly supported by the enhanced cell proliferation observed in renal cell carcinoma carrying the t(6;11)(p21:q13) translocation, which leads to a *TFEB* promoter substitution with the 5′ upstream regulatory sequence of the *alpha* intronless gene (Calcagnì *et al*, [2016](#embj201798250-bib-0005){ref-type="ref"}). The lack of promoter‐mediated physiological control of TFEB expression promotes clonogenic cell growth (Haq & Fisher, [2011](#embj201798250-bib-0024){ref-type="ref"}). In ECs, besides controlling autophagic flux (Fan *et al*, [2018](#embj201798250-bib-0018){ref-type="ref"}; Fig [6](#embj201798250-fig-0006){ref-type="fig"}D and E) our data indicate that TFEB exerts a more direct effect on cell proliferation. TFEB deletion reduced the expression of genes belonging to the "regulation cell cycle" GO, and most importantly, it directly bound the promoter of *CDK4*, an activator of G1‐S transition of cell cycle. The reduced availability of CDK4 impaired the phosphorylation of Rb, which relieves the Rb‐mediated inhibition of the transcription factor E2F involved in the expression of cell cycle‐related genes (Malumbres & Barbacid, [2009](#embj201798250-bib-0037){ref-type="ref"}). Interestingly, E2F is able to activate autophagy genes (Polager *et al*, [2008](#embj201798250-bib-0049){ref-type="ref"}), supporting the emerging concept that authophagy and cell cycle are not mutually exclusive processes (Mathiassen *et al*, [2017](#embj201798250-bib-0040){ref-type="ref"}). Therefore, the dual positive effects of TFEB on authophagy and cell cycle are not necessarily a paradox, but they may therefore depend on the temporal context and stimuli. It is possible to speculate that when TFEB is active to trigger the clearance of senescent cells by autophagy, it can initiate the machinery involved in the cell renewal.

However, the vascular phenotype observed in Tfeb mutants cannot be simply explained by the down‐modulation of CDK4 and the other cell cycle‐related genes.

VEGFR2 is considered the master gene of vascular development and angiogenesis in adult life (Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}). Therefore, the alterations of VEGFR2 biology here observed can contribute to explain the vascular phenotype of Tfeb mouse mutants. We speculate that in an attempt to compensate the cell cycle defect triggered by TFEB deletion, ECs increased the amount of PM VEGFR2, which, however, showed signaling limitations. In murine and human ECs lacking TFEB, we demonstrated the down‐modulation of the expression of intragenic miR‐15a/16‐1 cluster, which specifically targets the VEGFR2 3′UTR (Chamorro‐Jorganes *et al*, [2011](#embj201798250-bib-0007){ref-type="ref"}; Chan *et al*, [2013](#embj201798250-bib-0009){ref-type="ref"}) and the subsequent post‐transcriptional stabilization of *VEGFR2* mRNA. We also show that *TFEB* silencing increased the expression of the motor protein MYO1C, which functions as a cargo transporter (Greenberg & Ostap, [2013](#embj201798250-bib-0022){ref-type="ref"}), and it has been reported to deliver VEGFR2 to PM (Tiwari *et al*, [2013](#embj201798250-bib-0068){ref-type="ref"}). Actually, MYO1C silencing restored the effect of T*FEB* deletion on the co‐localization between VEGFR2 and Rab4^+^ vesicles, which are involved in the receptor exocytosis. These data are consistent with previous observations that the amount of membrane VEGFR2 is reduced by *MYO1C* depletion, whereas *MYO1C* overexpression rescues VEGFR2 at the PM (Tiwari *et al*, [2013](#embj201798250-bib-0068){ref-type="ref"}; Jopling *et al*, [2014](#embj201798250-bib-0029){ref-type="ref"}; Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}). However, the increased expression of VEGFR2 and its localization at PM were not paralleled by increased receptor signaling.

Actually, in sh‐TFEB ECs we reported the decrease in the phosphorylation of VEGFR2 in Y1175, which represents a docking site for PLCγ (Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}) and of the downstream signal molecules c‐Src and Erk1/2.

This discrepancy can be explained by the effect of TFEB on VEGFR2 membrane localization and trafficking. First in sh‐TFEB ECs, the PM accumulated VEGFR2 defectively co‐localized with CAV‐1‐rich domains, which are hotspots for signaling activity and required for VEGFR2 activation (Cho *et al*, [2004](#embj201798250-bib-0010){ref-type="ref"}). Second, when TFEB was knocked down, we observed an alteration of receptor trafficking analyzed by biotinylated VEGFR2 internalization, FACS, and TIRF. Of note, the accumulation of VEGFR2 induced by the inhibition of endocytic (Sawamiphak *et al*, [2010](#embj201798250-bib-0055){ref-type="ref"}; Gourlaouen *et al*, [2013](#embj201798250-bib-0021){ref-type="ref"}) and recycling (Ballmer‐Hofer *et al*, [2011](#embj201798250-bib-0002){ref-type="ref"}; Lanahan *et al*, [2013](#embj201798250-bib-0033){ref-type="ref"}) pathways leads to the inhibition of its signaling including the activation of PLCγ and MAP kinases.

The existence of extensive cross‐talks of autophagic and lysosome pathways with the mechanisms fueling endocytosis is well demonstrated (Pavel & Rubinsztein, [2017](#embj201798250-bib-0046){ref-type="ref"}).

Therefore, it is intriguing to speculate that the canonical effect of TFEB on endothelial autophagic flux (see Fig [6](#embj201798250-fig-0006){ref-type="fig"}D and E) negatively influences the VEGFR2 endocytosis, which is known to be important in its signaling (Simons *et al*, [2016](#embj201798250-bib-0062){ref-type="ref"}).

Altogether, these observations shed light on the TFEB‐mediated cellular mechanisms regulating VEGFR2 expression and allow a better understanding of the observed vascular phenotype in Tfeb mutants.

The *in vivo* vascular defects observed in *Tfeb* ^EC−/−^ and *Tfeb* ^iEC−/−^ mice validated the concept that one of the major consequences of *TFEB* deletion is the reduction of EC proliferation and the impairment of VEGFR2 activity. After the establishment of the primitive vascular plexus, the formation of the vascular tree is promoted by sprouting angiogenesis, which is characterized by the presence of either migratory tip cells or proliferating stalk cells. Tip cells guide network expansion, while stalk cells proliferate behind the tip cells to extend the vascular lumen as the sprouts elongate. The crucial role of VEGFR2 in this scenario has been demonstrated by experiments performed with ECs derived from embryonic stem cells, in which cells that are heterozygous for the *Vegfr2* allele show defects in stalk--tip dynamics (Jakobsson *et al*, [2010](#embj201798250-bib-0028){ref-type="ref"}).

EC *Tfeb*‐deficient embryos died between E10.5 and E11.5, displaying defects in the patterning of several regions of the vascular tree, with a reduction in larger caliber vessels and the capillary network. The effect of TFEB presumably begins after the formation of primitive vascular plexus because *Tfeb* deletion did not affect the appearance of hemangioblasts. Furthermore, post‐natal vascular maturation in the retina and kidney was altered in *Tfeb* mutants, with reduced proliferation. In *Tfeb* mutants, the retinal vasculature presented a delayed expansion of the vascular plexus and a significant reduction in vessel density. However, the ability of tip cells to extend filopodia was unaffected. This phenotype resembles that caused by the concomitant endothelial ablation of *Vegfr2* and *Vegfr3*, in which the vascular hyperplasia caused by *Vegfr3* deletion is counterbalanced by the absence of *Vegfr2* (Zarkada *et al*, [2015](#embj201798250-bib-0074){ref-type="ref"}), or by enhanced Notch activity in stalk cells (Phng *et al*, [2009](#embj201798250-bib-0048){ref-type="ref"}; Guarani *et al*, [2011](#embj201798250-bib-0023){ref-type="ref"}).

The deletion of *Tfeb* in renal ECs impairs the maturation of the glomerulus, a process that is strictly dependent of the VEGF‐A/VEGFR2 axis (Esser *et al*, [1998](#embj201798250-bib-0017){ref-type="ref"}). We observed a deep alteration of the cellular structures with the fusion of podocyte foot processes and the disappearance of endothelial fenestrae. Generally, the formation of the filtration barrier is regulated by a paracrine mechanism involving VEGF‐A released by podocytes and VEGFR2 expressed on glomerular ECs. The phenotype observed in *Tfeb* mutants is similar to that described in whole‐body post‐natal deletion of *Vegfr2* and podocyte‐specific *Vegfa* knockout (Eremina *et al*, [2003](#embj201798250-bib-0015){ref-type="ref"}; Sison *et al*, [2010](#embj201798250-bib-0063){ref-type="ref"}). Interestingly, pre‐ or post‐natal *Vegfa* deletion in podocytes promotes nephrotic syndrome or thrombotic microangiopathy, respectively (Eremina *et al*, [2003](#embj201798250-bib-0015){ref-type="ref"}, [2008](#embj201798250-bib-0016){ref-type="ref"}).

Altogether, these data bring new insight into the regulatory effect of TFEB in vascular cells (Lu *et al*, [2017](#embj201798250-bib-0036){ref-type="ref"}; Fan *et al*, [2018](#embj201798250-bib-0018){ref-type="ref"}) by activating a genetic program regulating cell proliferation and VEGFR2 functions. We speculate that TFEB represents a powerful cellular tool that connects vascular needs with the metabolic state. Recent data indicate that cellular nutrient levels regulate TFEB concentrations through an autoregulatory feedback loop, in which TFEB binds to its own promoter in a starvation‐dependent manner and induces its own expression (Settembre *et al*, [2013a](#embj201798250-bib-0060){ref-type="ref"}) and that TFEB negatively regulates the level of hypoxia‐inducible factor‐1 (Hubbi *et al*, [2013](#embj201798250-bib-0026){ref-type="ref"}). Furthermore, TFEB controls lipid breakdown, and its overexpression activates fatty acid oxidation (Settembre *et al*, [2013a](#embj201798250-bib-0060){ref-type="ref"}), which is necessary for sprouting angiogenesis, by fueling *de novo* nucleotide synthesis for DNA duplication (Schoors *et al*, [2015](#embj201798250-bib-0056){ref-type="ref"}).

Furthermore, the recent observation that shear stress up‐regulates TFEB (Lu *et al*, [2017](#embj201798250-bib-0036){ref-type="ref"}) allows hypothesizing its role in regulating the optimal PM amount of VEGFR2, which, through a multimeric complex with VE‐cadherin, PECAM‐1, and VEGFR3 (Baeyens *et al*, [2016](#embj201798250-bib-0001){ref-type="ref"}), transduces the frictional force from blood flow into biochemical signals that regulate gene expression and cell behavior.

Materials and Methods {#embj201798250-sec-0014}
=====================

Antibodies {#embj201798250-sec-0015}
----------

Anti‐GFP and anti‐Ki67 (SP6) from Thermo Fisher Scientific; isolectin‐B4, anti‐MYO1C, and anti‐α‐tubulin (B‐5‐1‐2), anti‐LAMP1, anti‐PCNA (PC10) from Sigma‐Aldrich; anti‐CD31, anti‐FLK1‐APC‐conjugated (Avas12alpha1), anti‐CD71‐FITC‐conjugated (C2), anti‐CD117 (2B8)‐PE‐cy7‐conjugated, anti‐CD31‐FITC‐conjugated (Mec 13.3), anti‐CD102, anti‐IgG~2a~ k isotype~‐~APC‐conjugated (R3595), anti‐IgG2bk isotype‐PE‐Cy7 conjugated (2B8), anti‐CD326, anti‐Rab4, and anti‐Rab5 from BD Biosciences; anti‐VEGFR2 (55B11), anti‐p‐Tyr‐1175‐VEGFR2 (D5B11), anti‐PLCγ‐1, anti‐p‐Tyr‐783‐PLCγ‐1, anti‐ERK1/2, anti‐p‐ERK‐1/2 (T202/Y204; E10), anti‐Src (36D10), anti‐p‐Src (Tyr416; D49G4), anti‐CDK4 (D9G3E), anti‐Rb (4H1), anti‐p‐Rb (Ser780; C84F6), and anti‐p‐Rb (Ser807/811; D20B12), anti‐PCNA (PC10), anti‐ULK1 (D8H5), anti‐ATG9A (D409D) from Cell Signaling Technology; anti‐endomucin (V.7C7), anti‐Flk‐1 (A‐3), anti‐podocin (G‐20), anti‐caveolin‐1 (N‐20) and anti‐E2F2 (TFE‐25), anti‐E2F1 from Santa Cruz Biotechnology; anti‐human VEGFR2 (89109) from R&D System; anti‐TFEB from MyBiosource; hypoxyprobe‐1‐FITC‐conjugated antibody (Chemicon); anti‐LC3 from Novus Biologicals; anti‐cyclin D1 (SP4), anti‐E2F1, and anti‐TGN46 (2F7.1) from Abcam.

Mice {#embj201798250-sec-0016}
----

All animal procedures were approved by the ethics committee of the University of Turin and by the Italian Ministry of Health (Protocol approval no. 864/2015‐PR).

To generate transgenic mice expressing Tfeb‐GFP, the sequence for the open reading frame of EGFP was inserted between the last amino acid and the translation termination codon in exon 9 (NCBI transcript NM_001161722.1). The positive selection marker (puromycin resistance---PuroR) was flanked by FRT sites and was inserted into intron 8. The targeting vector was generated using BAC clones from the C57BL/6J RPCIB‐731 BAC library and was transfected into the TaconicArtemis C57BL/6N Tac ES cell line. Homologous recombinant clones were isolated using positive (PuroR) and negative (thymidine kinase---Tk) selection. The constitutive KI allele was obtained after Flp‐mediated removal of the selection marker. The Tfeb‐EGFP fusion protein was expressed from the endogenous Tfeb promoter. The remaining recombination site was located in a non‐conserved region of the genome.

Endothelium‐specific silencing of Tfeb was achieved by crossing Tfeb^flox^ mice (Settembre *et al*, [2013a](#embj201798250-bib-0060){ref-type="ref"}) with the following: (i) transgenic mice expressing Cre‐recombinase driven by the Tie2 promoter (*Tie2‐Cre*; The Jackson Laboratory) to obtain a line with constitutive silencing of Tfeb in the endothelium (*Tfeb* ^*EC*^); and (ii) transgenic mice expressing tamoxifen‐inducible Cre‐recombinase (Cre‐ER^T2^) driven by the vascular endothelial cadherin promoter (*Cdh5‐Cre‐ER* ^*T2*^; *Tfeb* ^*iEC*^). *Tfeb* ^*floxed*^ */Cre* ^*+*^ mice (indicated respectively as *Tfeb* ^*EC*−/+^ or *Tfeb* ^*EC*−/−^ and *Tfeb* ^*iEC*−/+^ or *Tfeb* ^*iEC*−/−^ in the consideration of *Tfeb* deletion in heterozygosis or homozygosis) were compared with *Tfeb* ^*floxed*^ */Cre* ^*−*^ (without Cre) mice of the same progenies (indicated as control). Inducible Cre was activated by daily tamoxifen administration from p1 to p3 (1 mg/ml, 50 μl by intragastric injection) or from p5 to p8 (2 mg/ml, 50 μl by i.p. injection; Pitulescu *et al*, [2010](#embj201798250-bib-0506){ref-type="ref"}). To exclude tamoxifen pathological effects, both control mice that *Tfeb* ^*iEC*−/+^ and *Tfeb* ^*iEC*−/−^ mice were treated.

The systemic effect of *Tfeb* deletion was evaluated by analyzing hematological and biochemical parameters in blood after 1 month from the Cre induction (p0‐p8) in *Tfeb* ^*iEC*−/−^ mice. Mice survival was of 32.4 ± 5.9% (mice *n* = 24, *P* = 0.003 versus control mice), without any significant modification of renal and hepatic functions. However, the *Tfeb* ^*iEC*−/−^ mice only presented an increase of % reticulocytes (950.5 ± 200.8% versus 516.2 ± 107.1% in control mice; mice *n* = 10; *P* = 0.04) and % platelets (98.25 ± 27.24% versus 31.75 ± 15.3% in control mice; mice *n* = 10; *P* = 0.006).

\% point prevalence of vascular alterations was evaluated at E10.5 (our point time). Briefly, after endomucin immunostaining of the vessels, embryos with genotypes blindly analyzed (*n* = 25) were divided into two groups: "positive embryos" showing vascular alterations and "negative embryos" with absence of vascular defects. Following that, we separated the embryos of the two groups accordingly to their genotype (control, *n* = 13; *Tfeb* ^EC−/−^, *n* = 12) and the % point prevalence in control or *Tfeb* ^EC−/−^ embryos was calculated as: $$\begin{array}{cl}
{\%\mspace{720mu}\text{Point\ prevalence}\mspace{720mu} =} & {\mspace{720mu}(n\mspace{720mu}\text{positive\ embryos}/n\mspace{720mu}\text{positive\ embryos}} \\
 & {+ n\mspace{720mu}\text{negative\ embryos})\, \times \, 100} \\
\end{array}$$

Cells, genetic manipulation, and biological assays {#embj201798250-sec-0017}
--------------------------------------------------

Lung ECs were isolated from control and *Tfeb* ^*iEC*^ mice by positive selection with anti‐CD31 and anti‐CD102 Abs conjugated to Dynabeads and maintained *in vitro* up to passage 2 in M199 with 20% FCS. Lung epithelial cells were isolated with the same procedure by using anti‐CD326 Ab and maintained up to passage 2 in DMEM with 10% FCS. When *Tfeb* silencing was not induced *in vivo* (as previously described) but *in vitro*, lung ECs were incubated with 4‐OH‐tamoxifen (5 μM, 48 or 72 h) to allow *Cre* activation and *Tfeb* silencing. The correct recombination of the *Tfeb* allele was verified by real‐time PCR (Power SYBR Green PCR Master Mix). PCR was performed using specific primers (5′‐GACTCAGAAGCGAGAGCTAACAG‐3′ and 5′‐TGGCCTTGGGGATCAGCATT‐3′) recognizing the exon 5‐6 region of *Tfeb*.

*In vitro* experiments were carried out on human endothelial cells (indicated as ECs) isolated from umbilical cord veins maintained as described previously (Napione *et al*, [2012b](#embj201798250-bib-0505){ref-type="ref"}). To minimize cell variability, pools of 5 different donors were used. The isolation of primary human ECs was approved by the Office of the General Director and Ethics Committee of the Azienda Sanitaria Ospedaliera Ordine Mauriziano di Torino hospital (protocol approval no. 586, October 22, 2012; and no. 26884, August 28, 2014), and informed consent was obtained from each patient. Cells were tested for mycoplasma contamination by means of Venor GeM Mycoplasma Detection Kit.

The *TFEBS142A* mutant was generated from TFEB cDNA (Origene, cod. SC122773) by inserting a single point mutation using the Phusion Site‐Directed Mutagenesis Kit. TFEBS142A was cloned into the pTRIPZ inducible vector, and the transgene was induced by doxycycline addition (0.5 μg/ml) for 3 h (for ChIP‐seq experiments) or 24 h (other experiments). These cells were indicated as TFEBS142A. ECs infected with pTRIPZ‐TFEBS142A but not treated with doxycycline were used as control and indicated as "control". To exclude unspecific doxycycline effects, no infected ECs were also treated.

Loss‐of‐function experiments were carried out with shRNA against TFEB (\#1 TRCN0000013111, \#2 TRCN0000437429, \#3 TRCN0000013110, \#4 TRCN0000437246, and \#5 TRCN0000440038 NM_007162.2) or *MYO1C* (Catalog number \#1 TRCN0000122925, \#2 TRCN0000122927, \#3 TRCN0000122928 NM_033375) and *DLEU2* (Catalog number \#1 TRCN0000072484 and \#2 TRCN0000072485 NR_002612) cloned into the pLKO.1‐puro non‐Mammalian vector. In particular, the different experiments were performed with shRNA \#1 TRCN0000013111 against TFEB, shRNA \#1 TRCN0000122925 against MYO1C, and shRNA \#1 TRCN0000072484 against DLEU2. ECs were transduced with specific lentiviral particles (MOI = 1) prepared according to (Follenzi *et al*, [2000](#embj201798250-bib-0501){ref-type="ref"}) in the presence of 8 μg/ml polybrene. The medium was replaced after 24 h, and cells stably expressing the lentivirus were selected on puromycin (1 μg/ml) for 24 h. ECs were transfected with the appropriate control (miR‐inhibitor/miR‐mimic control) has‐miR‐15a‐5p and has‐miR‐16‐5p mirVana^TM^ miRNA inhibitors or mimics (90 nmol/l, 24 h) using Lipofectamine^®^ RNAiMAX Reagent. We verified the degree and the specificity of miRNA inhibition or up‐regulation and the eventually off‐target effects using qPCR (see specific section).

Proliferation rate and DNA content were evaluated by using Click‐iT^®^ EdU Flow Cytometry Cell Proliferation Assay and propidium iodide (PI) staining according to manufacturer\'s protocol. Briefly, human or lung murine ECs (5 × 10^6^) were starved overnight and then stimulated with 20% FCS or VEGF‐A (30 ng/ml) for 24 h. After 1‐hr incubation with 10 μM thymidine fluorescent analog 5‐ethynyl‐2′‐deoxyuridine (EdU), cell suspensions were processed for EdU detection and cell DNA was labeled by a 3‐h treatment with 50 μg/ml PI and 100 μg/ml ribonuclease A. Data were acquired with a CyAn ADP flow cytometer (Dako) and analyzed with FlowJo software (Tree Star, Ashland, OR, USA).

EC chemotaxis and morphogenesis were assayed and analyzed as described previously (Serini *et al*, [2003](#embj201798250-bib-0057){ref-type="ref"}). In particular, in morphogenesis assay ECs (2 × 10^4^) were resuspended with poor MEM and loaded on the top of the growth factor reduced Matrigel. Each conditional group contained 6 wells. Following incubation at 37°C for 6 h with VEGF‐A (30 ng/ml), each well was fixed with 4% paraformaldehyde, permeabilized in PBS 1% Triton X‐100, and stained with phalloidin‐555 and DAPI.

Yolk sac cells analysis {#embj201798250-sec-0018}
-----------------------

Yolk sacs from control or *Tfeb* ^*EC*^ embryos were collected at E9.5‐E10.5 and genotyped as described above. Each yolk sac was treated separately to obtain single‐cell suspensions by incubation with collagenase/dispase at 37°C for 1 h with occasional trituration. The samples were then subjected to flow cytometry analysis (see specific section).

Tissue and cell staining and analysis {#embj201798250-sec-0019}
-------------------------------------

Whole‐mount samples were prepared (Yokomizo *et al*, [2012](#embj201798250-bib-0072){ref-type="ref"}) by fixing tissues in 4% paraformaldehyde for 1 h on ice. Tissues were incubated overnight at 4°C in DPBS, 1% Triton X‐100, containing the indicated Abs. After washes, tissues were incubated for 1 h in the same buffer containing the appropriate Alexa Fluor secondary Abs. After fixation with 4% paraformaldehyde for 30 min at RT, samples were flat‐mounted onto glass coverslips.

Tissue sections were frozen in OCT compound and cut into 6--10‐μm thick sections. Embryo kidney and lung slices were fixed in 4% paraformaldehyde and Zinc fixative, respectively, for 10 min at room temperature, permeabilized, stained as indicated, and then incubated with the appropriate fluorescently labeled secondary Ab.

Hypoxia was detected by the formation of pimonidazole adducts 1 h after intraperitoneal (i.p.) injection of 60 mg/kg pimonidazole hydrochloride in pregnant females. Mice were then sacrificed, and the embryos were harvested and immunostained with hypoxyprobe‐1‐FITC‐conjugated Ab.

Immunofluorescence staining of vessels was manually quantified using ImageJ software after excluding any small‐sized, not‐interconnected objects. Immunoreactivity was calculated as the surface area of each Ab staining co‐localized with the EC markers endomucin, isolectin B4, or CD31 and normalized to the total vascular surface area visualized by the same molecules. The number of branching points per field was quantified as described previously (Samarelli *et al*, [2014](#embj201798250-bib-0053){ref-type="ref"}).

To quantify differences in the average length and total number of filopodia between control and *Tfeb* ^iEC^ mice, we used custom‐made image analysis algorithms written in MATLAB. (MATLAB and Image Processing Toolbox, The MathWorks, Inc., Natick, Massachusetts, United States.) Briefly, confocal stacks were maximum projected and then processed to obtain filopodia or the main vascular network. To extract main vascular network, images were median filtered and thresholded, and then, the external perimeter of the vasculature was measured. As for filopodia, images were filtered with a linear rotating kernel filter (Lee *et al*, 1990) and then processed with a multiscale vessel enhancement filter (Frangi *et al*, [1998](#embj201798250-bib-0502){ref-type="ref"}). Quantifications were based on the total length of the segmented filopodia divided by the total perimeter of the main vascular network and average length of major axis of each of the filopodial structure identified.

For transmission electron microscopy, mice were perfused with fixative buffer (2.5% glutaraldehyde and 2% paraformaldehyde in 0.15 M sodium cacodylate buffer). Kidneys were immediately placed into fresh fixative and then cut into small cubes. The analysis was performed at the Department of Cellular and Molecular Medicine, UCSD (La Jolla, CA).

For cell immunofluorescence staining, ECs (7 × 10^4^), grown up on cover slides, were fixed in 4% paraformaldehyde, permeabilized (PBS 0.1% Triton X‐100) and then incubated with the indicated primary Abs and the appropriate Alexa Fluor secondary Abs.

FACS {#embj201798250-sec-0020}
----

Cell suspensions from dissociated yolk sacs were incubated with indicated specific Abs and then analyzed on a CyAn ADP Analyzer (Beckman Coulter). DAPI‐positive dead cells were excluded from analysis. Cytosolic and PM VEGFR2 staining was performed using an IntraPrep kit (Beckman Coulter), and the data were analyzed using Summit 4.3 software (Beckman Coulter). The following Abs were used: anti‐VEGFR2‐PE‐conjugated (89106); anti‐IgG~1‐~PE‐conjugated (11711); anti‐CD202b (Tie2)‐PE‐conjugated (Tek4); anti‐IgG~1~ k isotype~‐~PE‐conjugated (RTK2071); anti‐FLK1‐APC‐conjugated (Avas12alpha1); anti‐IgG~2a~ k isotype~‐~APC‐conjugated (R3595); anti‐CD71‐FITC‐conjugated (C2); anti‐IgG~1~ k isotype~‐~FITC‐conjugated (R3‐34); anti‐CD117‐PE‐Cy7‐conjugated (2B8); and anti‐IgG2bk isotype‐PE‐Cy7 conjugated.

TIRF microscopy {#embj201798250-sec-0021}
---------------

TIRF microscopy was performed using a Leica AM TIRF MC system mounted on a Leica AF 6000LX workstation with a 63× oil‐immersion objective and a laser penetration depth of 110 nm. ECs were fixed, saturated and permeabilized, and then treated with Ab anti‐VEGFR2 (A3) and appropriate Alexa Fluor secondary Ab.

Quantification of immunofluorescence analysis {#embj201798250-sec-0022}
---------------------------------------------

Immunofluorescence images were acquired on a TCS SPE or TCS SP8 STED confocal laser‐scanning microscopes (Leica Microsystems). Different fields (tissue samples: 15--20; cell samples: 5--8) per sample section were randomly chosen for analysis. When the same molecule was evaluated in different samples, laser power, gain, and offset settings were maintained. Images were quantified using ImageJ software or TCS SP8 quantification software. For each analysis, at least 3 different experiments were performed.

Microarray experiments {#embj201798250-sec-0023}
----------------------

RNA extracted using a miRNeasy Mini Kit was amplified and labeled using an Illumina TotalPrep RNA Amplification Kit, and 750 ng of cRNA probe was hybridized to a HumanHT‐12 v4.0 Expression Bead Chip. All experiments were performed in triplicate. Cubic spline‐normalized probe intensity data, together with detection *P*‐values, were obtained using GenomeStudio software V2011.01. We selected probes with a detection *P* \< 0.05. For each gene, we retained the associated probe with the largest mean expression value across all samples. For each probe, the log~2~ signal was converted to the log~2~ ratio against the global average expression of that probe in all samples. Data were clustered using Gene Expression Data Analysis Suite (GEDAS; [www://gedas.bizhat.com](http://www://gedas.bizhat.com)), and LIMMA (Smyth, [2002](#embj201798250-bib-0064){ref-type="ref"}) was used to identify the modulated genes. A threshold \| log~2~ FC \| of \> 0.5 and an adjusted *P* \< 0.1 were used to select differentially expressed genes. Statistical analyses were performed in the R environment (<http://www.R-project.org>).

GSEA was performed using the public platform at <http://www.broadinstitute.org/gsea/msigdb/downloads.jsp>. In particular, after gene filtering for all the datasets, probes were collapsed on Gene Symbols, again selecting the probe with the largest mean expression across all the experiments for each gene. GSEA statistics were calculated with the default settings based on a Pearson metric. *P*‐values and FDRs were calculated by repeating sample permutations 1,000 times. The data were further analyzed for enrichment in biological themes (GO---Biological Processes, Molecular Functions, Cellular Components) by using the DAVID resource (<http://david.abcc.ncifcrf.gov>).

miRs annotation {#embj201798250-sec-0024}
---------------

We defined a set of miRs associated with angiogenesis on the basis of published literature with evidence based on experimental data (Chamorro‐Jorganes *et al*, [2013](#embj201798250-bib-0008){ref-type="ref"}). For each miR, we considered the corresponding pre‐miR based on the annotations provided by the Ensembl database, version Human GRCh37 (GENCODE 19, miRBase 18). In case the miR was intragenic, we identified the host gene and selected only those originating from the same DNA strand. Of these, we further chose only miRs with VEGFR2 as a validated target (Chamorro‐Jorganes *et al*, [2011](#embj201798250-bib-0007){ref-type="ref"}; Chan *et al*, [2013](#embj201798250-bib-0009){ref-type="ref"}). Finally, for this short list of candidates, we checked significant TFEB binding peak(s) in the putative core promoter region of the host gene.

ChIP‐seq {#embj201798250-sec-0025}
--------

For genome‐wide analysis of TFEB binding, sequencing libraries were constructed using the NEBNext^®^ ChIP‐seq Library Prep Reagent Set for Illumina and a NextSeq 500 Illumina sequencer. ChIP‐seq reads were aligned to the hg19 genome assembly using Bowtie v0.12.7 with the following parameters: ‐q --max/dev/null ‐v 1 ‐S --sam‐nohead ‐m 1. Data were filtered using the following specifications: Duplicate reads were filtered out. BedGraph files were generated by using MACS tool. Peak calling was performed as described previously (Krepelova *et al*, [2014](#embj201798250-bib-0503){ref-type="ref"}) using a *P*‐value cutoff = 1E‐08. TFEB target genes were defined as those having a peak between −500 and +100 from the annotated transcription start site.

ChIP {#embj201798250-sec-0026}
----

Chromatin immunoprecipitation of TFEB was performed as described previously (Krepelova *et al*, [2014](#embj201798250-bib-0503){ref-type="ref"}). Briefly, approximately 2 × 10^7^ crosslinked ECs were resuspended in 250 μl of SDS lysis buffer (10 mM EDTA, 1% SDS, 16.7 mM Tris, pH 8) with protease inhibitors and incubated for 10 min on ice. After sonication, the cell lysate was centrifuged at 12,000 *g* for 10 min at 4°C. The supernatant was diluted ten‐fold with ChIP dilution buffer (16.7 mM Tris--HCl, pH 8.0, 167 mM NaCl, 1.2 mM EDTA, 1% Triton) before immunoprecipitation.

The supernatant was incubated with 5 μg of Ab anti‐TFEB or IgG with rotation at 4°C for 16 h. Samples treated with IgG were used as a negative control. Afterward, previously BSA‐saturated beads (Dynabeads^®^ Protein G) were added for 2 h. Immunoprecipitated complexes were extensively washed before adding SDS elution buffer (50 mM Tris--HCl, pH 8.0, 10 mM EDTA, 1% SDS, DTT 5 mM, NaCl 150 mM) for 30 min at room temperature. After decrosslinking, DNA was purified using a QIAQuick PCR Purification Kit according to the manufacturer\'s instructions.

Luciferase reporter assay {#embj201798250-sec-0027}
-------------------------

Cells were seeded in 24‐well plates at a density of 4 × 10^4^ cells per well. After ChIP‐seq analysis, to identified the relative TFEB MACS peak on the different promoter gene, ECs were transfected with CDK4‐luciferase full‐length promoter (from J. Modiano, Addgene plasmid \#86656) and CDK4‐luciferase fragment A (from J. Modiano, Addgene plasmid \#86658) in which the predicted ChIP‐seq TFEB peak near TSS on CDK4 promoter is deleted. ECs were transfected with pMCS‐CypridiLuc_AC167_MYO1C_promoter (sequences −1,500/+200 from TSS of the longest isoform of MYO1C gene according to Ensembl GRCh37, transcript ID: ENST00000359786), pMCS‐CypridiLuc_AC167_MYO1C_promoter_d1 (in which the putative TFEB binding site has been deleted), pMCS‐CypridiLuc_AC167_MYO1C_promoter_d2 (in which 100 bps around the same putative TFEB binding site has been deleted) synthesized Geneart support (Thermo Fisher Scientific) and with pMCV‐GreenReLuc using Lipofectamine^®^ RNAiMAX Reagent according to the manufacturer\'s instructions.

Luciferase activities were analyzed with Pierce Cypridina Luciferase Glow Assay Kit and Pierce Renilla Luciferase Glow Assay Kit or The Dual‐Luciferase^®^ Reporter (DLR™) Assay System using a Glomax 20/20 luminometer (Turner Biosystems, Sunnyvale, CA, USA). The relative reporter activity was calculated by normalizing the luciferase activity with Renilla luciferase activity.

Western blot {#embj201798250-sec-0028}
------------

Western blotting and quantitative analysis using a ChemiDoc Touch Imaging System (Bio‐Rad) and Image Lab software 5.2.1 (Bio‐Rad) were performed as described (Napione *et al*, [2012a](#embj201798250-bib-0042){ref-type="ref"}) with the use of specific Abs above indicated. The following Abs were used: anti‐TFEB; anti‐VEGFR2 (55B11), anti‐p‐Tyr‐1175‐VEGFR2 (D5B11), anti‐PLCγ‐1, anti‐p‐Tyr783‐PLCγ‐1, anti‐ERK‐1/2, anti‐p‐ERK‐1/2 (T202/Y204; clone E10), anti‐Src (36D10), anti‐p‐Src (Tyr416; D49G4), anti‐CDK4 (D9G3E), anti‐Rb (4H1), anti‐p‐Rb (Ser780; C84F6) and anti‐p‐Rb (Ser807/811; D20B12), anti‐PCNA (PC10), anti‐ULK1 (D8H5), anti‐ATG9A (D409D); anti‐LC3; anti‐CD31; anti‐MYO1‐C, anti‐LAMP1, and anti‐α‐tubulin (B‐5‐1‐2); anti‐cyclin D1 (SP4), anti‐E2F1, and anti‐E2F2 (TFE‐25).

Biochemical analysis of PM distribution of VEGFR2 {#embj201798250-sec-0029}
-------------------------------------------------

ECs were starved in M199 for 3 h and then stimulated with VEGF‐A at 37°C (30 ng/ml) to allow VEGFR2 internalization. Cells were placed at 4°C, and the remaining receptors on PM were labeled with 0.15 mg/ml of impermeant sulfo‐NHS‐SS‐biotin in PBS for 10 min. The unreacted biotin was quenched with TBA (25 mM Tris, pH 8, 137 mM NaCl, 5 mM KCl, 2.3 mM CaCl~2~, 0.5 mM MgCl~2~, and 1 mM Na~2~HPO~4~), and ECs were solubilized in lysis buffer (20 mM Tris, pH 7.5, 125 mM NaCl, 10% glycerol, 1% NP‐40, protease inhibitor cocktail). This fraction represents the total cellular VEGFR2. PM biotin‐VEGFR2 complexes were separated from total VEGFR2 (biotin‐free) using streptavidin‐agarose beads (Napione *et al*, [2012a](#embj201798250-bib-0042){ref-type="ref"}). After protein extraction from the beads, equivalent volumes of the PM and total samples were resolved by SDS--PAGE and blotted with specific Abs. Loading controls were performed with an anti‐CD31 or α‐tubulin Abs.

VEGFR2 internalization assay {#embj201798250-sec-0030}
----------------------------

VEGFR2 internalization assays were performed as previously described (Valdembri *et al*, [2009](#embj201798250-bib-0069){ref-type="ref"}). ECs were PM‐labeled at 4°C with 0.5 mg/ml sulfo‐NHS‐SS‐biotin in PBS for 30 min on ice. Labeled cells were washed with cold MEM 1% FBS and cold PBS, and endocytosis was induced using prewarmed MEM, 1% FBS, containing VEGF‐A (30 ng/ml) and 0.1 M primaquine. At the indicated times, ECs were transferred to ice, and biotin was removed from the PM by incubation with 20 mM sodium 2‐mercaptoethanesulfonate (MesNa) in 50 mM Tris--HCl (pH 8.6), 100 mM NaCl, and 0.015N NaOH for 1 h at 4°C. MesNa was quenched by the addition of 20 mM iodoacetamide for 10 min. Cells were lysed in a specific buffer at 4°C (25 mM Tris--HCl, pH 7.6, 100 mM NaCl, 2 mM MgCl~2~, 1 mM Na~3~VO~4~, 0.5 mM EGTA, 1% Triton X‐100, 5% glycerol, protease inhibitor cocktail). The levels of biotinylated VEGFR2 were determined by Capture ELISA. Briefly, Maxisorp 96‐well plates were coated overnight with 5 μg/ml of anti‐VEGFR2 (89109) Ab at 4°C and were blocked in PBS containing 0.1% Tween‐20 with 5% BSA for 1 h at RT. VEGFR2 was captured by overnight incubation of the cell lysate at 4°C. Unbound material was removed by washing, and the wells were incubated with streptavidin‐conjugated horseradish peroxidase for 1 h at 4°C. Biotinylated VEGFR2 was detected with a chromogenic reaction.

The percentage of internalization of VEGFR2 was calculated as the percent of biotin‐VEGFR2 complexes in cell lysates after VEGF‐A stimulation with respect to all the biotin‐VEGFR2 complexes in unstimulated cells.

"Antibody feeding assay" was performed as previously described (Gourlaouen *et al*, [2013](#embj201798250-bib-0021){ref-type="ref"}). ECs were incubated for 3 h in serum‐free M199 medium at 37°C; then, PM VEGFR2 was labeled with anti‐VEGFR2 extracellular domain Ab (R&D System) for 30 min at 4°C; and then, cells were fixed or transferred to prewarmed serum‐free M199 medium containing VEGF‐A (30 ng/ml) at 37°C for 15 min to permit internalization. Cells were then incubated with the anti‐Rab5 Ab and the appropriate Alexa Fluor secondary Abs.

Statistical analysis {#embj201798250-sec-0031}
--------------------

Sample sizes were not selected according to a specific power analysis but just in agreement with similar experiments done in other laboratories working in vascular development and quoted in the specific references. No statistical methods were used to predetermine sample size.

We did not randomize sample/animals because our experimental design did not require this type of strategy. The investigators were not blinded to allocation during experiments and outcome assessment. The data are indicated as the mean ± SEM. Statistical analyses were performed using unpaired Student\'s *t*‐test (two‐tailed) or one‐way ANOVA, followed by post hoc pairwise analysis tests, as indicated using GraphPad Software (La Jolla, CA, USA, [www.graphpad.com](http://www.graphpad.com)). A *P* \< 0.05 was considered significant.
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